Copyright NeuroRx, Inc. ©2020 All Rights Reserved   
 
 
 
Clinical Study Protocol  
 
RLF -100 for the Treatment  of Critical COVID -19 with 
Respiratory Failure   
  
Protocol : RLF100 -001 
 
Principal Investigator s Dushyantha Jayaweera, MD  
Professor of Medicine   
University of Miami, Miller School of Medicine  
 
Jihad Georges Youssef, MD  
Chair, Academic Pulmonary Medicine  
Houston Methodist Hospital  
Study Sponsor  
 
Study Chair  NeuroRx , Inc.  
913 North Market Street, Suite 200  
Wilmington, DE  19801  
Jonathan C. Javitt, MD, MPH  
IND Number  
Phase  IND 149152  
Phase 2b/3 
IRB Approved  
Version  
Date  V.4.7   
26-Dec-2020  
 
 
 
 
 
 
 
 

           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 2 
 SYNOPSIS  
Name of Investigational 
Product:  RLF-100  
Name of Active 
Ingredient:  Aviptadil  
Reference Product(s):  Vasoactive Intestinal Polypeptide (synthetic)  
Title of Study:  RLF-100 for the Treatment of Critical COVID -19 with Respiratory Failure   
Phase of Development:  Phase 2b/3 
Study Site(s):  Multi Center : University of Miami , UC Irvine, Houston Methodist , and others  
Total Participant Number:  198 evaluable (mITT) subjects  with Critical COVID -19 on mechanical ventilation  
(for <8 days) , non-invasive ventilation  or high flow rate nasal cannula at minimum 
20L flow and 50% FIO 2  
 
 Study Duration:  60-day total follow -up 
Background and 
Rationale:  The research to be conducted under this protocol references Phase 1 research 
conducted under IND 52,088 in which Vasoactive Intestinal Polypeptide (VIP) has 
previously shown suggestions of efficacy in the treatment of ARDS related to sepsis, 
pulmonary arterial hypertension and other respiratory disorders.  
Objectives:  To demonstrate the efficacy of RLF -100 in improving survival and reducing 
respiratory distress / requirement for mechanical ventilation in patients with Critical 
(NIH/FDA definition) COVID -19 receiving maxim um standard of care  other than 
extracorporeal mem brane oxygenation (ECMO).  
Endpoint(s):  Primary Outcome Measure:   
1) Cumulative distribution of the time to respiratory failure resolution with 
concurrent survival through Day 28.  
 
Key Secondary Measure:  
2)  NIAID Ordinal Scale for Clinical Improvement (Scores 6 -8) through Day 28  
 
Secondary Outcome Measures (through Day 28  unless otherwise specified ): 
3) Survival lifetable  through Day 28 and through Day 60  
4) Time to ICU discharge  
5) Time on invasive mechanical ventil ation  
6) Time on non -invasive ventilation  
7) Time to discharge alive  
8) Multi -organ failure free days  
9) NIAID Area under the curve (AUC)  
 
Other Outcome Measures (through Day 28) : 
10) Respiratory Distress while on mechanical ventilation:  
Blood PaO2/FiO2 ratio [Time  Frame: enrollment through extubation]  
11) Oxygenation Index  
12) Improvement in chest x -ray 
13) IL-6, TNFα and other inflammatory markers  
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 3 
Study Design:  Patients with Critical COVID -19 who are receiving Maximal Standard of Care 
(SOC) therapy that includes non -invasive high pressure or mechanical ventilation 
will be randomized to intravenous Aviptadil + Maximal SOC vs. Placebo + Maximal 
SOC, escalating from  50 pmol/kg/hr to 150 pmol/kg/hr.  
 
 
 
 
 
  Inclusion Criteria:  1) Primary Cohort: Critical COVID -19 (test positive in past 7 days) with 
respiratory failure by NIH/FDA definition  requiring either mechanical 
ventilation, non -invasive ventilation or high flow rate nasal cannula at 
minimum 20L flow and 50% FIO 2. No more than 7 days of mechanical 
ventilation.  
2) Physician commitment to maximum Standard of Care as deemed necessary  
Exclusion criteria:  1) Pregnancy  
2) Age <18 years  
3) Mechanical ventilation for more than 7 days in primary cohort.  
4) Mean Arterial Pressure < 65 mm Hg  with use of pressor per ICU protocol  
5) Irreversible  condition (other than COVID -19) with projected fatal course  
6) ECMO  
7) Current or recent (within 30 d) enrollment in another investigational trial  of 
anti-IL6 drug or immunomodulator drug ; 
8) Active diagnosis of Acquired  immune  deficiency  syndrome;  
9) Transplant patients currently immunosuppressed ;  
10) Chemotherapy -induced neutropenia (granulocyte count <1000/mm3);  
11) Cardiogenic shock; congestive heart failure – NYHA Class 3 or 4;  
12) Recent myocardial infarction  – within last 6 months and troponin > 0.5  
13) Anuria (urine output < 50 ml/d)  or other signs of multi -organ failure   
14) Severe liver disease with portal hypertension  or bilirubin 4.0 or higher ;  
15) Recent stroke or head trauma within last 12 months  
16) Increased intracranial pressure, or other serious neurologic disorder;  
17) Liquid diarrhea  more than 3x/day; defined as more than 3 non -bloody watery 
stools within a 24 -hour period, requiring additional fluid and electrolyte 
supplementation  
 
Safety Assessments:  A safety analysis was conducted by the Data Monitoring Committee at 21 patients. 
All p atients will be surveilled for Serious Adverse Events (SAE).  All SAEs will be 
reported to independent Data Safety Monitoring Board and to FDA  
Dosage, Route of 
Administr ation, and 
Schedule:  Three escalating doses of RLF-100 (A viptadil ): 50, 100, and 150 pmol/kg/hour or 
placebo administered over 12 hours via IV infusion on successive days.  If side 
effects cannot be managed with ICU protocol , dose reduced or halted.  
Statistical Methods:  Primary endpoint (cumulative distribution of the time to respiratory failure 
resolution) with concurrent survival through Day 28 will be displayed by a lifetable 
through Day 28 and analyzed using a proportional hazard model analysis containing 
4 pre -define d baseline covariates and randomized treatment group (primary) as well 
as an unstratified log rank test (secondary). Primary endpoint ascertainment requires 
that recovery from respiratory failure be maintained for at least 7 days without 
relapse. The cumul ative distribution will be constructed through Day 28 with no 
censoring for death or withdrawal; such patients will be regarded as failures. Other 
time to event outcomes will be similarly analyzed with the exception of survival 
which will censor for any wi thdrawals.  NIAID Score will be analyzed by carrying 
forward any early deaths through Day 28; other ordinal and continuous outcomes 
will be assessed by mixed model repeated measures through Day 28.  The primary 
analysis will be based on the modified intent -to-treat (mITT) population to be based 
on all treated patients.  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 4 
Sample Size Calculation:  For the primary efficacy endpoint, assuming a 40% success percent in the placebo 
group by Day 28 and a 62% success percent in the RLF -100 group by Day 28, for 
log rank test with two -sided overall 5% Type 1 error and 8 1% power, the sample size 
to detect a 2 2% absolute improvement in the percent achieving respiratory failure 
resolution by Day 28 (from 40% to 62%) is 1 98 subjects in the primary analysis 
group (2:1 randomization favoring the RLF -100 group).  A 20% absolute advantage 
in the percent achieving respiratory failure resolution by Day 28 is deemed to be 
clinically meaningful.  
Interim Analyses  An interim look fo r safety and futility will be conducted once the first 21 randomized 
subjects complete Day 7.  A second interim look for safety, futility, and efficacy will 
be conducted once the next 81 subjects complete Day 28  but the study will not be 
prematurely stoppe d for efficacy .  
Maintenance of  
Study Blind  Investigational drug will be administered in identical infusion bags , labeled by the 
hospital research pharmacist who is the only unblinded member of the study site.  
ICU personnel are entirely masked as to trea tment assignment, as are patients.  Even 
in the event of unintentional unblinding because of differential efficacy or safety of 
the investigational medicinal products (drug and placebo), the randomization scheme 
prevents staff from knowing the next treatme nt assignment.  Moreover, the primary 
and declared secondary endpoints are not subject to interpretation by ICU staff.  
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 5 
 CONTACT INFORMATION  
Role in Study  Name  Telephone  / Email  
 
National Co -Chairs  
 Dushyantha Jayaweera, MD  
Jihad Georges Youssef, MD   
djayawee@med.miami.edu  
jgyoussef@houstonmethodist.org  
 
Sponsor  Study Chair  Jonathan Javitt, MD, MPH  202-340-1352  
jjavitt@neurorxpharma.com  
 
ISRG Biostatistician  Philip Lavin, PhD, FASA,  FRAPS  phil_lavin@hotmail.com  
Chair, Independent  
Data Safety Monitoring Board  Prof. Alfred Sommer, MD, MHS  asommer@jhu.edu  
 
 
Rest of Page Left Intentionally Blank  
 
 PROTOCOL SIGNATURE PAGE  
I have read this protocol and agree to adhere to the requirements. I will provide copies of this protocol 
and all pertinent information to the study personnel under my supervision. I will discuss this material 
with them and ensure they are fully informed regarding the conduct of the study according to 21 CFR 
parts 50, 54, 56 and 812, 45 CFR 46, to GCP, as described in ICH guideline E6 and to hospital 
Institutional Review Boards.  
 
 
_____________________________    _____________ ________  
Clinical Site Investigator Signature     Date  
 
 
_____________________________  
Clinical Site Investigator Printed Name  
 
 
_____________________________    _____________________  
Sponsor Signature     Date  
 
Jonathan C. Javitt, MD, MPH  
  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 6 
 TABLE OF CONTENTS  
 
 SYNOPSIS  ................................ ................................ ................................ ................................ ..........................  2 
 CONTACT INFORMATION  ................................ ................................ ................................ ................................ .. 5 
 PROTOCOL SIGNATURE PAGE  ................................ ................................ ................................ ...........................  5 
 TABLE OF CONTENTS  ................................ ................................ ................................ ................................ .........  6 
 LIST OF ABBREVIATIONS  ................................ ................................ ................................ ................................ ... 8 
 INTRODU CTION ................................ ................................ ................................ ................................ .................  9 
6.1 EXECUTIVE SUMMARY  ................................ ................................ ................................ ................................ ...........  9 
6.2 DEFINITION OF CRITICAL COVID -19 ................................ ................................ ................................ ........................  9 
6.3 RLF-100  EXPERIMENTAL THERAPY IN COVID -19 ................................ ................................ ................................ .... 10 
6.4 AVIPTADIL BACKGROUND  ................................ ................................ ................................ ................................ .... 10 
6.5 CLINICAL RATIONALE  ................................ ................................ ................................ ................................ ..........  10 
 OBJECTIVES  ................................ ................................ ................................ ................................ .....................  10 
7.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ ...........  10 
7.2 SECONDARY OBJECTIVE  ................................ ................................ ................................ ................................ .......  11 
 STUDY DESIGN  ................................ ................................ ................................ ................................ ................  11 
8.1 OVERVIEW  ................................ ................................ ................................ ................................ ........................  11 
8.2 DESIGN  ................................ ................................ ................................ ................................ ............................  11 
8.3 NUMBER OF PARTICIPANTS  ................................ ................................ ................................ ................................ .. 12 
8.4 STUDY DESIGN  ................................ ................................ ................................ ................................ ..................  12 
8.5 RLF-100  TREATMENT PROTOCOL  ................................ ................................ ................................ .........................  13 
8.6 ANTICIPATED RISK ................................ ................................ ................................ ................................ ..............  13 
 SELECTION OF SUBJECTS  ................................ ................................ ................................ ................................ . 13 
9.1 STUDY POPULATION  ................................ ................................ ................................ ................................ ...........  13 
9.2 INCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ...........  14 
9.3 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ............  14 
 RECRUITMENT, CONSENT & ENROLLMENT  ................................ ................................ ................................ ..... 14 
10.1 RECRUITMENT & CONSENT PROCEDURES  ................................ ................................ ................................ ...............  14 
10.2 OBTAINING INFORMED CONSENT  ................................ ................................ ................................ ..........................  14 
10.3 PROTECTING CONFIDENTIALIT Y ................................ ................................ ................................ .............................  15 
10.4 HIPAA  COMPLIANCE  ................................ ................................ ................................ ................................ ..........  15 
10.5 STANDARD OF CARE SUPPORT  ................................ ................................ ................................ ..............................  15 
10.6 POPULATION BIAS ................................ ................................ ................................ ................................ ..............  15 
10.7 ENROLLMENT  ................................ ................................ ................................ ................................ ....................  15 
10.8 RANDOMIZATION PROCEDURES  ................................ ................................ ................................ ............................  15 
10.9 PROCEDURE FOR MAINTAINING THE BLIND ................................ ................................ ................................ .............  15 
 TREATMENT OF SUBJECTS  ................................ ................................ ................................ ...............................  16 
11.1 MAXIMAL STANDARD OF CARE ................................ ................................ ................................ .............................  16 
11.2 PROPER STANDARD OF CARE (SOC)  MANAGEMENT PRINCIPLES  ................................ ................................ .................  16 
11.3 PLACEBO  ................................ ................................ ................................ ................................ ..........................  16 
11.4 DOSING REGIMEN  ................................ ................................ ................................ ................................ ..............  17 
11.5 POTENTIAL SIDE EFFECTS OF DRUG THERAPY  ................................ ................................ ................................ ...........  17 
 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ................................ . 17 
12.1 SERIOUS ADVERSE EVENTS  ................................ ................................ ................................ ................................ ... 17 
12.2 DEFINITION OF ADVERSE EVENTS  ................................ ................................ ................................ ..........................  17 
12.3 DEFINITION OF A SERIOUS ADVERSE EVENT  ................................ ................................ ................................ .............  17 
12.4 RELATIONSHIP TO STUDY DRUGS  ................................ ................................ ................................ ...........................  18 
12.5 RECORDING OF ADVERSE EVENTS  ................................ ................................ ................................ ..........................  18 
12.6 REPORTING OF ADVERSE EVENTS  ................................ ................................ ................................ ..........................  18 
12.7 REPORTING OF SERIOUS ADVERSE EVENTS  ................................ ................................ ................................ ..............  18 
 ASSESSMENT OF EFFICACY  ................................ ................................ ................................ ..............................  18 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 7 
13.1 DATA COLLECTION  ................................ ................................ ................................ ................................ .............  18 
13.2 MAINTENANCE OF BLINDING  ................................ ................................ ................................ ................................  19 
13.3 PRIMARY EFFICACY ENDPOINT  ................................ ................................ ................................ ..............................  19 
13.4 KEY SECONDARY ENDPOINT  ................................ ................................ ................................ ................................ . 20 
13.5 ASSESSMENTS OF ENDPOINTS  ................................ ................................ ................................ ...............................  20 
 STATISTICAL ANALYSIS  ................................ ................................ ................................ ................................ .... 21 
14.1 STATISTICAL DESIGN AND ANALYSES  ................................ ................................ ................................ ......................  21 
14.2 SAMPLE SIZE CALCULATION  ................................ ................................ ................................ ................................ .. 22 
14.3 STUDY POPULATIONS  ................................ ................................ ................................ ................................ ..........  22 
14.4 STATISTICAL METHODS  ................................ ................................ ................................ ................................ .......  22 
14.5 INTERIM ANALYSIS , FUTILITY /SAFETY  ................................ ................................ ................................ .....................  23 
 HYPOTHESIS TESTS  ................................ ................................ ................................ ................................ ..........  24 
15.1 TREATMENT COMPARISONS  ................................ ................................ ................................ ................................ . 24 
15.2 PRIMARY HYPOTHESIS  ................................ ................................ ................................ ................................ .........  24 
15.3 PRIMA RY EFFICACY ENDPOINT : COMPOSITE SUCCESS  ................................ ................................ ................................  24 
15.4 KEY SECONDARY EFFICACY ENDPOINT : TIME TO RESOLUTION OF RESPIRATORY FAILURE  ................................ ..................  25 
15.5 SECONDARY EFFICACY ENDPOINT : BLOOD PAO2/F IO2 RATIO (WHILE ON MECHANICAL VENTILATION ) ...............................  25 
15.6 SECONDARY EFFICACY ENDPOINT : OXYGENATION INDEX  ................................ ................................ ............................  26 
15.7 SECONDARY EFFICACY ENDPOINT : IMPROVEMENT IN CHEST X -RAY ................................ ................................ ..............  26 
15.8 SECONDARY EFFICACY ENDPOINT : NIAID  8-POINT SCALE AND AREA UNDER THE CURVE  ................................ .................  26 
15.9 SECONDARY EFFICACY ENDPOINT : SURVIVAL  ................................ ................................ ................................ ...........  26 
15.10  OTHER EFFICACY ENDPOINTS : ICU,  VENTILATIONS , EXTUBATION , AND DISCHARGE  ................................ ........................  26 
15.11  OTHER EFFICACY ENDPOINT : MULTI-SYSTEM ORGAN FAILURE  ................................ ................................ ....................  26 
15.12  LABORATORY EFFICACY ENDPOINTS : INFLAMMATORY MARKERS  ................................ ................................ .................  27 
15.13  OVERALL SAFETY ENDPOINTS  ................................ ................................ ................................ ...............................  27 
 SOURCE DATA & DOCUMENTS  ................................ ................................ ................................ ........................  27 
16.1 SOURCES OF RESEARCH MATERIALS  ................................ ................................ ................................ .......................  27 
16.2 CASE REPORT FORM ................................ ................................ ................................ ................................ ...........  27 
16.3 PATIENT IDENTIFICATION  ................................ ................................ ................................ ................................ ..... 28 
16.4 GENERAL CLINICAL DATA ................................ ................................ ................................ ................................ ..... 28 
16.5 LUNG INJURY / ARDS  DATA ................................ ................................ ................................ ................................  28 
16.6 LABORATORY DATA ................................ ................................ ................................ ................................ ............  28 
16.7 VITAL SIGNS, RESPIRATORY AND HEMODYNAMIC DATA ................................ ................................ .............................  28 
16.8 MEDICAL THERAPY DATA................................ ................................ ................................ ................................ ..... 28 
16.9 PHARMACOKINETIC SAMPLING  ................................ ................................ ................................ .............................  28 
16.10  BLOOD SAMPLING  ................................ ................................ ................................ ................................ ..............  28 
 STUDY MO NITORING  ................................ ................................ ................................ ................................ ...... 29 
17.1 STUDY MONITORING  ................................ ................................ ................................ ................................ ..........  29 
17.2 DATA SAFETY AND MONITORING  ................................ ................................ ................................ ..........................  29 
17.3 MEDICAL MONITOR  ................................ ................................ ................................ ................................ ...........  30 
17.4 AUDITS AND INSPECTIONS  ................................ ................................ ................................ ................................ .... 30 
17.5 INSTITUTIONAL REVIEW BOARD  ................................ ................................ ................................ ............................  30 
 ETHICAL CONSIDERATIONS  ................................ ................................ ................................ .............................  30 
18.1 ETHICAL CONSIDERATIONS  ................................ ................................ ................................ ................................ ... 30 
18.2 ETHICAL CONDUCT OF THE STUDY  ................................ ................................ ................................ .........................  30 
18.3 INFORMED CONSENT  ................................ ................................ ................................ ................................ ..........  31 
 DATA HANDLING & RECORD KEEPING  ................................ ................................ ................................ .............  31 
19.1 DATA CAPTURE  ................................ ................................ ................................ ................................ ..................  31 
19.2 DATA COLLECTION  ................................ ................................ ................................ ................................ .............  31 
19.3 RETENTION OF RECORDS  ................................ ................................ ................................ ................................ ..... 31 
19.4 USE OF INFORMATION AND PUBLICATION POLICY  ................................ ................................ ................................ ..... 31 
 REFERENCES  ................................ ................................ ................................ ................................ ....................  32 
 APPENDIX A; SCHEDULE OF EVENTS  ................................ ................................ ................................ ................  35 
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 8 
List of Tables  
 
No Tables Included  
 
List of Figures  
Figure 1 Study Sc hema ………………………………………………… 14 
Figure 2 Study Dosing    ………………………………………… …….. 15 
 
 LIST OF ABBREVIATIONS  
AA   Amino Acid  
ALI    Acute Lung Injury  
ARDS    Associated Acute Respiratory Distress Syndrome  
COVID -19  Corona Virus Disease 2019  
ECMO    Extracorporeal membrane  Oxygenation  
ED    Erectile Dysfunction  
EMR    Electronic Medical Record  
Fas   Cell Surface Death Receptor  
HCl   Hydrogen Chloride  
ICU   Intensive Care Unit  
ITT   Intent -to-Treat  
IL   Interleukin  
IND    Investigational New Drug  
IV   Intravenous  
SOC    Maximal Intensive Care  
MERS    Middle East Respiratory Syndrome  
MMRM   Mixed model repeated measures  
RDR    Respiratory Distress Ratio  
SOC    Standard of Care  
SAE    Serious Adverse Events  
SARS    Severe Acute Respiratory Syndrome    
SARS -CoV -2  SAR S-Coronavirus 2  
TNFα     Tumor Necrosis Factor Alpha 
VIP   Vasoactive Intestinal Peptide  
 
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 9 
 INTRODUCTION  
6.1 Executive Summary  
No therapeutic agent has demonstrated safety and efficacy in treating COVID -19 related Respiratory 
Failure. RLF -100™ (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP), a ubiquitous, 
naturally synthesized human peptide binds to the Alveolar Type II (ATII) cell in the pulmonary epithelium 
and inhibits SARS -CoV -2 replication, blocks cytokine synthesis, inhibits cytopathy, and upregulates 
production of surfactant.  The Coronavirus effect on the ATII cell causes the profound respiratory failure 
associated with COVID -19, perhaps precipitated by failure of surfactant production in the alveolus. RLF -
100™ has been granted Fast Track designation for the treatment of COVID -19 Respiratory Failure by the 
FDA and admitted to the CoronaVirus Treatm ent Acceleration Program.  
Aviptadil has a long history of human safety and  has previously been granted investigational new drug 
(IND) status by the US FDA and the EMEA for treatment of Acute Respiratory Distress Syndrome 
(ARDS), Acute Lung Injury (ALI), P ulmonary Fibrosis, and Sarcoidosis. At least five well -controlled 
studies have been conducted for the use of aviptadil in chronic lung conditions.   
VIP has demonstrated specific binding to pulmonary alveolar type II cells, which are the primary target of 
the SARS -CoV -2 virus. In the Type II cell, VIP upregulates surfactant production, inhibits SARS virus 
replication, inhibits cytokine production, and inhibits cytopathy  in numerous non -clinical models of SARS 
infection, ARDS , and ALI .  Aviptadil  has shown early evidence of efficacy in preserving life in patients 
with ARDS. A phase 1 safety trial of aviptadil was conducted in eight patients with sepsis -related ARDS, 
who had  an expected 50% mortality rate. Seven patients demonstrated clinical benefit based on improved 
blood oxygenation and were successfully withdrawn from advanced life support. Six of those patients 
survived long term and left the hospital, with one succumbin g to an unrelated myocardial infarction post 
ICU discharge. These results demonstrate in a phase 1 study that aviptadil significantly reduced expected 
mortality in patients with ARDS (mortality reduction of p<.01 vs historical controls). We propose RLF -
100 (aviptadil ) for the treatment of Critical COVID -19.  
6.2 Definition of Critical COVID -19 
In May 2020, FDA defined Critical COVID -19 to be used in clinical trials and disease staging as follows:  
Critical  
COVID -19 • Positive testing by standard RT -PCR assay or an equivalent test  
• Evidence of critical illness, defined by at least one of the following:  
o Respiratory Failure defined on resource utilization requiring at least one of 
the following:  
▪ Endotracheal intubation and mechanical ventilation, oxygen delivered by  
high-flow nasal cannula (heated, humidified, oxygen delivered via 
reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered 
oxygen ≥ 0.5), noninvasive positive pressure ventilation, ECMO, or 
clinical diagnosis of respiratory failure (i. e., clinical need for one of the 
preceding therapies, but preceding therapies not able to be administered in 
setting of resource limitation)  
o Shock (defined by systolic blood pressure <90 mmHg, or diastolic blood 
pressure <60 mmHg or requiring vasopressors)  
o Multi -organ dysfunction/failure  
Note that treatment with ECMO, mean arterial pressure <65 mmHg on pressors, and Multi -organ failure 
are exclusion criteria for this protocol  
Acute Lung Injury in COVID -19 is characterized by progressive failure of corporeal oxygenation, 
attributed on large part by SARS -CoV -2 infection of Alveolar Type II cells (Mason 2020). Extensive 
nonclinical studies document that 70% of VIP in the body binds to VPAC 1 receptors on the Alveolar Type 
II cell, where VIP is known to block cytokine production and upregulate production of surfactant.  
The pathologic hallmark of COVID -19 lung injury  is diffuse alveolar damage, vascular endothelium 
damage, and damage to the surfactant -producing type II cells which results in loss of the integrity of the 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 10 
alveolar -capillary barrier,  transudation of protein -rich fluid across the barrier, pulmonary edema,  and 
hypoxemia from intrapulmonary shunting.  Typically,  patients who have progressed to Critical COVID -19 
require care in an intensive care unit (ICU). The mortality rate is approximately 50%.  Deaths usually 
result from multisystem organ failure rather th an respiratory  failure alone.  
6.3 RLF -100 E xperimental Therapy in COVID -19 
Under this protocol,  patients with Respiratory Failure associated with Critical COVID -19 will be randomly 
allocated to intravenous  RLF-100™ (aviptadil), with the aim to support pulmonary alveolar function, 
combat the cytokine -induced inflammation, improve blood oxygenation, and reduce mortality.  
6.4 Aviptadil Background  
Aviptadil (vasoactive intestinal peptide; VIP) is an abundant biolog ically active peptide endogenous in 
humans as well as in other species. It is produced by neurons in the peripheral and central nervous system, 
by endocrine cells such as  pituitary lactotrophs , cells of the endocrine pancreas as well as T -lymphocytes, 
and B-lymphocytes. This natural  peptide is one of the signal molecules of the neuroendocrine -immune 
network comprising vasodilat ion, anti -proliferative, anti -inflammatory, an d immuno -suppressive features. 
Aviptadil  is predominantly localized in the lungs and a  vast body of experimental, pharmacological as well 
as clinical evidence suggests Aviptadil to be an attractive candidate as a treatment option for acute 
pulmonary disorders.  
Endogenous aviptadil is synthesized from a precursor molecule which contains 170 amino acids and is 
processed to its biologically active form via a signal peptidase in the endoplasmic  reticulum and finally 
cleaved by prohormone convertases and by carboxypeptidase -B like enzymes to functional Aviptadil 
comprising the following 28 amino acids: His -Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-
Lys-Gln-Met- Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn. 
Aviptadil was first identified in the intestine and then in the central and peripheral nervous system s and has 
since been recognized as  a widely distributed neuropeptide, acting as a neurotransmitter and 
neuromodulator in many organs and tissues, including heart, lung, thyroid gland, kidney, immune system, 
urinary tract and genital s. 
The widespread distribution of VIP is correlated with i ts involvement in a wide variety of physiological 
activities including smooth muscle relaxation, increased cardiac output, bronchodilation, immune -
modulation, inhibition of smooth muscle cell proliferation, anti -apoptosis, neurotropic effects, and some 
differential effects on secretory processes in the gastrointestinal tract and gastric motility.  
The rationale for the current application can be  summarized as follows: VIP binds to and protects the 
specific cell (the Alveolar Type II cell) that is attacked by the SARS -CoV -2 virus in COVID -19. Once 
bound to the cell via the VPAC1 receptor, VIP blocks viral replication, increases surfactant production, 
blocks cytokine synthesis, and blocks cell death (cytopathy) .  
6.5 Clinical Rationale  
Given by intraveno us infusion in appropriate concentrations, aviptadil  has been shown in clinical trials to 
have a manageable safety profile  with no observed SAEs to date that would rise to the level of a black box 
warning . In an administratively -controlled trial of patient s with COVID -19 respiratory failure and severe 
comorbidity (21 aviptadil -treated/24 controls), IV aviptadil dosed in 3 sequential infusions of 50/100/150 
pmol/kg/hr was associated with a 9 fold increase in probability of recovery from respiratory failure a nd a 
comparable increase in survival over 60 days.  
 OBJECTIVES  
7.1 Primary Objective  
The primary objective of this study is to test the hypothesis that  RLF-100 + maximal standard of care 
(SOC)  shortens  the time to respiratory failure resolution (see Section 6.2) in patients with Critical COVID -
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 11 
19 compared to those treated with placebo + maximal SOC , in both cases not including ECMO . 
7.2 Secondary Objective  
The key secondary objective is to test the hypothesis that RLF -100 + maxi mal SOC improves NIAID  
Score over the first 28 (primary)  and over the first 60 (secondary)  days (from pre -treatment) in patients 
with Critical COVID -19 compared to those treated with placebo + maximal SOC, in both cases not 
including ECMO.  
 STUDY DESIGN  
8.1 Overview  
This study, RLF100 -001, is a  multi -center , randomized double -blind, placebo -controlled phase 2 trial, 
comparing RLF-100 + Maximal SOC  to placebo + Maximal SOC . Aviptadil or placebo will be 
administered as a 12-hour IV  infusion on three consecutive days . Patient s with Critical  COVID -19 
infection will be  screened . Informed consent will be obtained from the patient or a responsible party . Once 
entered into the study, participants will be randomized in a 2:1 ratio of IV RLF -100 + maximal SOC  vs. 
placebo  + maximal SOC .  Once enrolled, patients assigned to rec eive RLF-100 will be given in three (3) 
doses of i.v.  infusion , each dose given over 12-hour period  at the same time on consecutive days , in 
escalating doses  from 50pmol/kg/hr to 150 pmol/kg/hr of RLF -100.   The primary outcome to be measured 
following RLF -100 infusion is the cumulative distribution of the time to respiratory failure resolution by 
28 days  with concurrent survival through 28 days .  The declared secondary outcome to be measured 
following RLF -100 infusion will be the improvement in baseline for the NIAID Score from pre -treatment 
baseline to Day 28/exit using the remdesivir criterion (NIAID Score 6 -8).  Respiratory failure is defined  as 
resource -based according to the FDA May 2020 respiratory failure definition  (see Section 6.2).  Eight  other 
secondary efficacy endpoints are also to be evaluated in support of multi -dimensional efficacy.  
8.2 Design  
Randomized, prospective , double -blind, pl acebo -controlled  trial of RLF -100 + maximal SOC  vs. Placebo + 
maximal SOC  therapy  in patients with Critical COVID -19. 
Following informed consent, patients will be  randomized and administered either placebo or  escalating 
doses of RLF -100 from 50 pmol/kg/hou r IV to 150 pmol/kg/hour as  three (3)  12 hour infusions  each at the 
same time  of day o n subsequent study days 1, 2, and 3. Vital signs and  telemetry  will be monitored 
throughout the infusion and for  48 hours after completion of all 3 infusions.  Pulmonary, cardiovascular, 
hepatic, CNS, renal, and coagulation functions will be assessed daily for 5 days, and plasma levels of 
aviptadil and selected cytokines will be measured.  
The primary efficacy outcome is a pre -defined cumulative distribution of the time to respiratory failure 
resolution during the 28 -day follow -up with concurrent survival .  In other words, recovery from respiratory 
failure in the absence of survival to the end of the observation period is not considered treatment success. 
The cum ulative distribution over the 28 -day interval is consistent with the recent remdesivir approval. 
However, because the patients enrolled in this trial are exclusively those in category 6 and 7 of the 
remdesivir  trial (where efficacy was not shown at 28 days) , we will evaluate their key secondary efficacy 
endpoint  (the percent achieving a NIAID Score 6 -8 by Day 28/exit and by Day 60 /exit). 
Secondary outcome measures will include the cumulative distribution  lifeta ble through Day 28  with 
attention paid to the Day 28 estimate from the lifetable.  Time to ICU discharge, time on invasive 
mechanical ventilation, time on non -invasive ventilation, and time to discharge alive  will be evaluated 
through Day 28. NIAID  area un der the curve (AUC)  will be evaluated through Day 28 . 
Other outcome measures to be evaluated through Day 28 include the blood PaO2/FiO2 ratio (enrollment 
through extubation), oxygenation index, improvement in chest x -ray, IL -6, TNFα and other inflammatory 
markers.  
The endpoint rationale is to include the traditional 28 -day all -cause mortality plus clinically meaningful 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 12 
endpoints indicative of multi -dimensional recovery.     
8.3 Number of Participants  
Initially, randomization will result in 14 participants to re ceive RLF -100 + SOC  and 7 participants to 
receive placebo + SOC  in the primary efficacy cohort comprised of patients who meet enrollment criteria 
and have been on mechanical ventilation for <8 days (including zero days for those not on mechanical 
ventilation) . The total number of participants may expand to 1 98 patient s (132 drug/ 66 placebo) if there are 
acceptable efficacy and safety  profiles at the interim analyses .  The analysis at 21 patients will be 
unblinded so this cohort will not be part of the final analysis but will be included in a supportive analysis 
since r esults remain confidential. Thus, the sample size for analysis purposes will be 198 patients for the 
primary analysis.  
8.4 Study Design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 shows a graphical schema of the RLF100 -001 protocol study design.  
Screen  
 
 
 
 
Randomize  
RLF 100  
vs. Placebo + 
MIC  
(2:1)  
IV 
3 infusions  
12 hrs each  
over 3 days  
Follow -up 
28 Days  
Primary Outcomes:  
•Cumulaive distribution of time to 
resp. failure  resolution by Day 28 
with Day 28 survival  
Key Secondary Outcome:  
•Proportion reaching NIAID 6 -8 by 
Day 28  
Secondary Outcomes:  
•Survival through Days 28 and 60  
•Time to ICU discharge  
•Time on invasive MV  
•Time on non -invasive MV  
•Time to hospital discharge alive  
•Multi -organ free days  
•NIAID area under the curve  
Placebo + 
MIC  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 13 
8.5 RLF -100 Treatment  Protocol  
Figure 2  shows  a graphical flow chart of the RLF100 -001 protocol study design.  
 
Note: The “check ABG” prompts in Figure 2 apply to ventilated patients with arterial lines  only.  These 
ABGs are to be carried out mid -infusion, at the 6 hou r timepoint.  
Note: If a determination is made to slow down the infusion rate by 50% - the next infusion would still be 
applied at the next 24 -hour period. (E.g. if infusion was started at 8:00 AM and it runs for 18 hours, the 
next infusion should still tak e place at 8:00 AM the following day.)   If infusion is halted, patient remains in 
the study. Physician can dose next day at last well -tolerated dose for a maximum of 3 doses.  
8.6 Anticipated Risk  
Reported adverse events for intravenous aviptadil include hypote nsion,  tachycardia,  facial flushing and 
watery diarrhea . If this were to develop, the infusion w ould be slowed or stopped  until resolved. See Flow 
Chart (Figure 2 above).  
 SELECTION OF SUBJECTS  
9.1 Study Population  
The trial will be conducted in hospitalized  patients with Critical COVID -19 by FDA/NIH criteria (section 
6.2.) Subjects must meet all the inclusion and none of the exclusion criteria to be qualified to participate in 
this study.  

           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 14 
9.2 Inclusion  Criteria  
All patients entered  this trial will have the diagnosis of Critical COVID -19 (test positive in past 7 days) . 
Subjects  will be  observed for a 1 to 24-hour period, during which time all inclusion criteria must be met. If 
all criteria are met once (not necess arily simultaneously),  the patient  will be  enrolled  and randomized to 
receive the study  drug or placebo  within  12 hours  of the following  entry  criteria  being  fulfilled:  
1) Critical COVID -19 with respiratory failure by NIH/FDA definition  requiring either mechanical 
ventilation, non -invasive ventilation, or high flow rate nasal cannula at minimum 20L flow and 50% 
FIO 2. 
2) Physician commitment to maximal Standard of Care treatment  – as deemed necessary  
3) Primary cohort: patients with less than 8 days of exposure to mechanical ventilation , non-invasive  
ventilation , or high flow rate nasal cannula at a minimum of 20L flow and 50% FIO 2. 
9.3 Exclusion Criteria  
1) Pregnancy  
2) Age <18 years  
3) Mechanical ventilation for more than 7 days in primary cohort.  
4) Mean Arterial Pressure < 65 mm Hg  with use of pressors per ICU protocol  
5) Irreversible  condition (other than COVID -19) with projected fatal course  
6) ECMO  
7) Current or recent (within 30 d) enrollment in another investigational trial  of anti -IL6 drug  or 
immunomodulator drug  
8) Active diagnosis of Acquired  immune  deficiency  syndrome.   
9) Transplant patients currently immunosuppressed.   
10) Chemotherapy -induced neutropenia (granulocyte count <1000/mm3 ).  
11) Cardiogenic shock; congestive heart failure – NYHA Class 3 or 4. 
12) Recent myocardial infarction  – within last 6 months and current troponin > 0.5 
13) Anuria (urine output < 50 ml/d)  or other signs of multi -organ failure   
14) Severe liver disease with portal hypertension; Bilirubin ≥4.0  
15) Recent stroke or head trauma within last 12 months  
16) Increased intracranial pressure, or other serious neurologic disorder.  
17) Liquid diarrhea  more than 3x/ day; defined as more  than 3 non -bloody watery stools within a 24-
hour  period, requiring additional fluid and electrolyte supplementati on 
 RECRUITMENT, CONSENT & ENROLLMENT  
10.1 Recruitment & Consent Procedures  
All admissions to the intensive care unit will be screened for fulfillment of inclusion criteria by the 
Principal Investigator . Direct patient consent is always preferred if possible, but p atients are sometimes 
unable to give consent in this setting. The PI or PI’s designee will seek consent from the patient’s 
responsible party, after explaining the procedure and consent form, approved by all participating sites. It 
should be noted that one feature of the COVID -19 pandemic is that non -patients are barred from hospital 
premises. Therefore, informed consent from responsible parties will generally be obtained telephonically 
and signature will be obtained via an SMS text message  or otherwise compliant consent systems (e.g . 
REDCAP) . Consent will be documented by a witnessed, consent form, to be kept on file  together with 
telephonic signature .  This does not preclude a site from obtaining consent via paper, if such arrangements 
can be  made, e.g. fax.   Should the patient regain ability to consent, consent will be sought accordingly.  
10.2  Obtaining Informed Consent  
Direct patient consent is always preferred if possible, but p atients are sometimes unable to give consent in 
this setting. IRB-approved written informed consent forms (ICF) will be obtained from the responsible 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 15 
party of all subjects before any protocol -specified procedures are carried out. For entry into the study, all 
inclusion criteria  must be met, and none of the exclusion criteria can be met. All signed ICF forms will be 
logged and kept in locked research cabinets or other restricted electronic system under the supervision of 
the local Site PI and available for audit upon request.  
10.3 Protecting Confidentiality  
Any information obtained in this study will be treated as confidential and will be safeguarded. The data 
will be coded and kept in a secure location.  When published, the results of the study will be in a form that 
does not identif y any of the patients. In compliance with federal regulations, the records of the study will 
be available to representatives of the Food and Drug Administration.  
10.4 HIPAA Compliance  
The study will be compliant with the Health Insurance Portability and Account ability Act (HIPAA), which 
protects the privacy and security of healthcare information. All personal identifying information (PII) will 
be securely stored and only accessible to healthcare providers and authorized personnel only.   
10.5 Standard of Care Support  
Supportive treatment in the ICU, including antibiotics, oxygen, mechanical ventilation, blood pressure -
supporting medications, and all other standard of care interventions as needed, will be continued, 
regardless of participation in the study.  
10.6 Population Bias 
For unknown reasons, males are affected by severe COVID -19 symptoms twice (2X) as often as are 
females. It is likely that the enrollment in this trial will be consistent with that gender difference . There is 
no evidence to suggest that RLF-100 will be  differently tolerated based on race.   
10.7 Enrollment  
The enrollment will be in accordance with a group sequential design . Up to 12 sites will participate.  
The sample size for analysis purposes well be 1 98 patients ( 132 drug/ 66 placebo) for the primary analysis.  
10.8 Randomization Procedures  
Randomization will be on a 2:1 basis with a random block size of 3 or 6; a centralized randomization will 
be used.  Subjects will be stratified according to RDR (<200 mmHg, >200 mmHg) and previou s anti -viral 
therapy for COVID -19 (none, any).  
Using this method, even if site personnel believe they can tell the difference between clinical reaction to 
RLF-100 vs. placebo, they have no possibility to guess what the next allocation will be.  
10.9 Procedure f or Maintaining the Blind  
Investigational drug will be delivered in identical infusion syringes, labeled by the hospital research 
pharmacist who is the only unblinded member of the study site.  ICU personnel are entirely blinded, as are 
patients.  Even in t he event of unintentional unblinding because of differential efficacy of drug and 
placebo, the randomization scheme prevents staff from knowing the next treatment assignment.  Moreover, 
the primary and declared secondary endpoints are not subject to interp retation by ICU staff.  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 16 
 TREATMENT OF SUBJECTS  
11.1 Maximal Standard of Care  
All patients entered in the trial receive Maximal Standard of Care treatment  and support, including fluids, 
antibiotics, vasoactive agents, non-invasive  or mechanical ventilation, hemodialysis, surgery,  and other 
supportive measures  excluding  extra -corporeal membrane oxygenation (ECMO).  Ventilation methods are:  
• Invasive mechanic al ventilation includes ventilation associated with an endotracheal or 
tracheos tomy tube.  Types of mechanical ventilation with this interface include volume -controlled 
and pressure -controlled ventilation. Examples are assist -control, pressure control and APRV  
• Non-invasive mechanical ventilation includes CPAP, BiPAP, NIPPV  (non-invasive positive 
pressure ventilation)  
• Oxygen delivery systems include HFNC, nasal cannula, non-rebreather mask, Airvo, oxygen hood, 
Oxymask, Oxymizer, simple face mask, and the Venturi mask. 
The need for ECMO will be considered a treatment failure on the basis that the lung has been deemed 
incapable of supporting adequate metabolic function. Decisions regarding the use of intravenous fluids, 
cardiovascular and respiratory support, a nd surgical intervention are made by each patient's attending 
physician and are not dictated by the study protocol. At the completion of the  three 12-hour infusions , 
patients are followed up to 60 days . The schedule of events reflects study plans to follow all patients for up 
to 60 days  even after discharge,  but it will not be practical during the Corona Pande mic either to bring 
patients back for post -discharge visits or to make home visits. Death while o n life support vs. death 
following discharge from mechanical ventilation will be tracked separately.  Discharge from mechanical 
ventilation means that the treating physicians have deemed the patient capable of breathing without the 
need for mechanical vent ilation.  A death that occurs because life support has been withdrawn in the 
absence of this determination will be recorded as death while on life support.  
11.2 Proper Standard of  Care ( SOC ) Management Principles  
Management principles are similar despite differ ent etiologies. Oxygenation must be maintained,  and the 
underlying  cause  of acute  lung injury  corrected.  Meticulous  attention is  necessary  to prevent  nutritional  
depletion,  O2 toxicity,  superinfection,  barotrauma,  and renal failure, which may be worsened by 
intravascular volume depletion. While the diagnosis  is being  considered,  life-threatening  hypoxemia  must  be 
treated  with a high FiO2 and monitored with repeated arterial blood gases or noninvasive oximetry. Prompt 
endotracheal  intubation  with mechanical  ventilation  and PEEP  may be needed  to deliver O 2 if hypoxemia  is 
refractory  to O2 inhalation  by face mask  or nasal cannula . Despite the presence of alveolar edema,  IV fluids  
should  be given  if needed  to restore  peripheral  perfusion,  urine  output, and BP. Monitoring  vascular  volume  is 
crucial  because  both hypovolemia  and overhydration are deleterious. Physical findings and central venous 
pressure may be misleading in critically  ill patients  undergoing  mechanical  ventilation,  and if severe  
hypoxemia  persists, if skin perfusion is poor, if mentation is impaired, or if urinary output decreases (< 0.5 
mL/kg/h),  a reliable  index  of intravascular  volume  is needed  immediately.   
ECMO is a lifesaving modality th at may be used when mechanical ventilation is unable to support life.  
However, the availability of ECMO is limited and decisions to allocate ECMO resources to patients are 
likely to be based on broader triage concerns.  Therefore, ECMO is not considered p art of SOC  for the 
purposes of this study and the decision to escalate care to ECMO will be considered a treatment failure for 
the purpose of this study on the grounds that it signifies a determination that the lung is unable to support 
life even with mech anical ventilation.  
11.3 Placebo  
A normal saline placebo will be supplied by the hospital pharmacy in a labeled container indistinguishable 
from active drug.  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 17 
11.4 Dosing Regimen  
The escalating dosing regimen for RLF -100 is shown in Figure 2.  Each infusion is planned for 12 hours 
duration, however, the infusion (either drug or placebo) may be slowed by up to 50% (for an 18-hour total 
infusion time) at the discretion of the site pe rsonnel  if side effects cannot be managed to a clinically -
acceptable level by the institution’s ICU protocol or SOC . Monitoring of vital signs and other safety 
measurements will be ongoing and decisions relating to dose -reduction or cessation will be based  on th e 
evaluation of these parameters.  
11.5  Potential Side Effects of Drug Therapy  
Signs  and symptoms to look for: facial flushing, tachycardia, hypotension, diarrhea. These will be 
monitored for the duration of the infusion, and for 12 h afterward, by blood pressure and heart telemetry  
measurements and patient observation . One identified sid e-effect of Aviptadil  infusion is watery diarrhea. 
As noted above, non-bloody watery diarrhea > 3x/day requiring additional fluids and electrolyte 
supplementation is an enrollment exclusion. If watery diarrhea  is observed during infusion, the infusion 
rate should be first reduced by 50% to relieve symptoms. If symptoms persist cease IV infusion.  
 ASSESSMENT  OF SAFETY  
12.1 Serious Adverse Event s  
Measurement of serious adverse events (SAE) will be the basis for assessing safety of RLF -100. All SAE’s 
will be r ecoded on an IRB approved SAE Report Form . The SAE Report Form will include the exact 
nature of the event and the circumstances of the subject at the time of the event, in addition to the usual 
information required to document AEs or SAEs. Data on all the above will be collected on separate eCRF 
pages.  The latest version of the AE dictionary, MedDRA, will be used for the classification and analysis of 
AEs entered in the study database. For regulatory reporting, SAEs will be coded using  MedDRA . 
12.2 Definition of  Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non -investigational) product. An AE does not necessarily have a causal 
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational 
or non -investigational) product, whether or not related to that medicinal (investig ational or non -
investigational) product. (Definition per ICH). AEs will be classified as drug -related, possibly drug -related, 
or non -drug related by the study safety monitor.  
12.3 Definition of a Serious Adverse Event  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes:  
1. Death,  
2. Life-threatening adverse events,  
3. Inpatient hospitalization or prolongation of existing hospitalization,  
4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
function, or  
5. Congenital anomaly or birth defect.  
 
If a serious and unexpected AE occurs for which there is evidence suggesting a causal relationship between 
the study drug and the event (e.g., death from anaphylaxis), the event must be reported as a serious and 
unexpected suspected adverse reaction even if it is a component of the study endpoint (e.g., all -cause 
mortality). In addition, the following variables w ill be collected for SAEs:   
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 18 
• Date AE met criteria for SAE  
• Date investigator became aware of SAE  
• Explanation of seriousness of this AE 
• Date of hospitalization  
• Date of discharge  
• Probable cause of death  
• Date of death  
• Autopsy performed  
• Causality assessment in relation to study procedure(s)  
• Causality assessment in relation to study drug  
• Causality assessment in relation to other medication  
• Description of AE  
12.4 Relationship to Study Drugs  
Adverse events and SAEs will be collected from the time of signat ure of informed consent throughout the 
treatment period. The investigator will assess the causal relationship (i.e., the relationship to study 
treatment) between the investigational product  and the AEs and answer “yes” or “no” to the question “Do 
you consi der that there is a reasonable possibility that the event may have been caused by the 
investigational product?” For SAEs, causal relationship will also be assessed.  
12.5 Recording of Adverse Events  
Abnormal and clinically significant lab values will be reporte d as AEs if they fulfill any of the SAE criteria 
or are the reason for discontinuation of treatment with the study drug. The principal investigator and the 
study biostatistician will establish the rules for what will constitute abnormal and clinically sign ificant lab 
values based on established site -specific lab normal ranges. Adverse events, including abnormal lab values 
(clinically significant and clinically non -significant), will be review ed monthly for trends by the principal 
investigator and the medica l monitor. Should any abnormal lab values exceed acceptable rates, the FDA 
will be notified within regulatory timelines. Wherever possible, the reporting investigator will use the 
clinical, rather than the laboratory term (e.g., anemia versus low hemoglobi n value).  
12.6 Reporting of Adverse Events  
All relevant AEs and special reporting situations, whether serious or non -serious, will be reported from the 
time a signed and dated Informed Consent Form (ICF) is obtained until completion of the subject’s last 
study -related procedure . All events that meet the definition of a SAE will be reported as SAEs, regardless 
of whether they are protocol -specific assessments.  All AEs, regardless of seriousness, severity, or 
presumed relationship to study drug, must be recorded u sing medical terminology in the source document 
and the eCRF. Whenever possible, diagnoses will be given when signs and symptoms are due to a common 
etiology . The sponsor assumes responsibility for appropriate reporting of AEs to the regulatory authorities . 
12.7  Reporting of Serious Adverse Events  
Reportable SAEs will be sent to the IRB and FDA by the sponsor. When a SAE is discovered, it will be 
reported immediately (within 24 business hours) to the Medical Monitor . Serious adverse events will be 
reported within 24 business hours of the site’s knowledge of the event to the  Sponsor, Medical Monitor, 
and study site investigators.  
 ASSESSMENT OF EFFICACY  
13.1 Data Collection  
Data will be collected via the electronic medical r ecord  (EMR) or other hospital information system and 
ICU telemetry systems. Once collected, data will be transferred by study personnel to the Target Health 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 19 
electronic data capture system, which has been audited by FDA in connection with multiple drug 
approvals. GCP will be observed throughout.  Extensive data  not already defined in this protocol will be 
available for analysis via the EMR and telemetry systems.  
13.2 Maintenance of Blinding  
Investigational drug will be delivered by infusion and  labeled by the hos pital research pharmacist who is 
the only unblinded member of the study site.  ICU personnel are entirely masked as to treatment 
assignment , as are patients.  Even in the event of unintentional blinding because of differential efficacy of 
drug and placebo,  the randomization scheme prevents staff from knowing the next treatment assignment.  
Moreover, the primary and declared secondary endpoints are not subject to interpretation by ICU staff.  
13.3 Intercurrent Events  
Given that this is an ICU study, the standard practice is to use the ICH E9 (R1) "treatment policy strategy" 
where all additional treatments given to the patient are considered to be part of care in both treatment 
groups.  Thus, the analysis does not contr ol for them but rather ignores them. Both remdesivir and 
dexamethasone will be considered in this way since there are no approved indications for Critical COVID -
19.  The treatment policy strategy is based on the ICH E9 ITT Principle.  Thus , the occurrence of an 
intercurrent event is considered irrelevant in defining the treatment effect of interest; the value for the 
variable of interest is used regardless of whether or not the intercurrent event occurs. For example, when 
specifying how to a ddress use of additional medication as an intercurrent event, the values of the variable 
of interest are used whether or not the patient takes additional medication.   The study further benefits in 
that study treatment is limited to three days so any subseq uent intercurrent event is considered to be part of 
the treatments being compared.  One situation where the treatment policy strategy cannot be implemented 
for intercurrent events that are terminal events, e.g. going on ECMO or dying since values for the v ariable 
after the intercurrent event do not exist ; then the estimand based on this strategy cannot be constructed with 
respect to a variable that cannot be measured due to death  or being put on ECMO .  Thus, dying or going on 
ECMO will impose a failure on a ll time to event outcomes other than survival.  
13.4 Dropouts  
Dropouts are not expected given that this is an ICU study.  In the event of dropouts (including early 
withdrawals), these events will be reviewed at a Biostatistics Data Review Meeting (BDRM) to deter mine 
(in a blinded manner) the impact on each efficacy endpoint as well as a n alternative impact to be applied in 
sensitivity analyses.   The general approach will be to consider early withdrawals from a best practices 
perspective; for example, a patient go ing home on Day 10 who refuses follow -up at Day 28 and Day 60 is 
likely alive where a patient being transferred to a hospice is to be assumed as dead at Day 28 and Day 60.  
13.5 Primary Efficacy Endpoint  
The original primary efficacy endpoint has changed from a binary composite endpoint originally suggested 
by the original FDA division to a cumulative distribution of respiratory failure resolution at the suggestion 
of the study Data Monitoring Committee held July 14, 2020.  The DMC counseled the use of a primary 
endpoint that would us e “all the data” available to establish a difference between drug and placebo.  The 
DMC recommended a time series approach, e.g. cumulative distribution, for the time to resolution of 
respiratory failure, originally a secondary endpoi nt but elevated to the primary endpoint .  
 
The new primary efficacy endpoint is thus consistent with the recent FDA approval of remdesivir for a less 
ill study population as informed by recent FDA input ( Reference ID: 4613030 NeuroRx, Inc .) in which 
FDA re commended the cumulative distribution of the time to resolution through Day 28  with concurrent 
Day 28 survival .  The endpoint is further informed by recent FDA guidance not released at the time of 
study inception.1  
 
1 Statistical Considerations for Clinical Trials During the COVID -19 Public Health Emergency   June 2020  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 20 
13.6 Key Secondary Endpoint  
Given the recent  remdesivir approval and publication, the percents achieving a NIAID Score 6 -8 by Day 
28/exit (primary) and by Day 60 /exit (secondary)  will be the key secondary endpoint which was the 
remdesivir primary efficacy endpoint.  
13.7 Assessments of Endpoints  
Cumulative Distribution: Resolution of Respiratory Failure  
The cumulative distribution will use all randomized and treated patients. Resolution of respiratory failure is 
defined as no mechanical or non -mechanical ventilation or high -flow nasal O 2. Primary endpoint 
ascertainment requires that recovery from respiratory failure be maintained for at least 7 days without 
relapse . Patients must survive through Day 28 to be counted as having resolved.  Any deaths irrespective of 
respiratory failure resolution or w ithdrawals without respiratory failure resolution will be counted as 
failures at Day 28; only documented resolution events will be counted as success in the distribution 
construction; this conservative approach is what was done for remdesivir. Imputing Day  28 failure  aligns 
the cumulative distribution curve with the cumulative respiratory failure free days.  A 20% absolute 
advantage is considered to be clinically meaningful.  
 
NIAID 8 -point scale  
The NIAID 8 -point scale will be used as a measure of recovery from Critical COVID -19.  NIAID Scores 
will be collected daily through hospital disch arge and at Day 28 and at Day 60.  All on -study deaths 
(NIAID Score= 1) will be carried through Day 28/exit  and Day 60/exit .  The distribution of the improvement 
will be ass essed relative to the pre -treatment baseline.  The percents achieving a NIAID Score 6 -8 by Day 
28/exit (primary) and by Day 60 /exit (secondary)  will be of interest from a regulatory and clinical 
perspective to be consistent with the rem desivir approval.   
 
Survival  
Survival lifetables will be constructed through Day 28 and then through Day 60.  Patient death is defined as 
asystole. Data will be collected on whether the death occurred after withdrawal of care and, if so, the reason 
for withdrawal of care.  Patient death is most likely to occur where the patient was hospitalized. Data will 
be collected on whether the death occurred after withdrawal of care and, if so, the care withdrawal reason.     
 
Time to Events  
Secondary time to event outcome measures include time to ICU discharge, time on invasive mechanical 
ventilation  (subgroup analysis) , time on non -invasive ventilation  (subgroup analysis) , time to discharge 
alive, and time to resolution of organ failure  through Day 28 .  In addition,  the Day 28 estimate from each 
lifetable will be analyzed.  These endpoints will be displayed and analyzed in the same way as the time to 
respiratory failure resolution.  Any deaths irrespective of an event (all favorable) or withdrawals without the 
event will be counted as failures at Day 28; only documented events will be counted as success in the 
distribution construction; this conservative approach is consistent with what was done for remdesivir. 
Imputing Day 28 failure  aligns the cumulative distributio n curve with the cumulative event days.  
 
Index of Respiratory Distress  
The PaO 2/FiO 2 ratio shall be calculated from the continual telemetry data obtained from the ICU 
information system and arterial blood gas (ABG) for patients while on mechanical ventilat ion. This variable 
is not useful after O 2 on mechanical ventilation has been reduced because the ratio is reduced even though 
oxygenation is already improving .  In the absence of an arterial line, ABG’s will be collected only when 
medically indicated.  
 
Oxygenation Index  
The Oxygenation index is defined as:  
 
 
 
Inflammatory Markers  

           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 21 
TNFα and other cytokine studies will be performed by the central lab.  Note that these are not declared 
efficacy or safety endpoints.  
 
Improvement in Chest x -ray 
Chest x -ray images will be collected (1) pre -treatment, (2) 48 -96 hours post start of infusion, (3) 1 week ±2 
days post start of infusion, and (4) two weeks ± 2 days post start of infusion, provided the patient is still 
hospitalized.  All x -rays will be read by a blind ed radiologist panel and scored according to the Rapid 
Assessment of Lung Edema (RALE) score (Warren 2017).   
 
Clinical decision to terminate mechanical ventilation  
Study research personnel will collect all available data regarding the clinical decision -making that guides 
removal mechanical ventilation in relation to clinical deterioration or lack of clinical response (e.g. change 
in status to comfort measures, poor prognosis for  recovery, allocation of resources in a pandemic setting,  
etc.).  
 
Additional d ata to be collected  
Because of the unique nature of this study and the circumstances under which it is being conducted, at 
FDA’s request, sponsor will collect all data regarding the use of experimental therapeutic agents (e.g. 
hydroxychloroquine, IL -6 inhi bitors, and other topics of interest) and deliver those data to FDA for further 
analysis.  Sponsor will make this analysis data set available to the broader scientific community as well.    
13.8 Patient Follow -up Strategies  
 
This study begins with the patients in the ICU and could end with the subject still in the ICU, in another 
hospital, at home, or deceased.  Every possible effort has been taken to minimize dropouts and losses to 
follow -up.  The following actions have been taken  to ensure follow -up: 
 
1. encourage sites to establish  reliable  follow -up networks with patients for use post discharge . 
2. follow an algorithm that includes multiple communication/information gathering strategies to 
starting with 3  documented  telephone calls, followed by fit for purpose use of text messages, email, 
next of kin/contact person outreach, review of system medical records as appropriate, primary 
physician follow up, public records and, again if appropriate, locator services.   
 
Thus, we expect the los s to follow -up in this study to be quite low.  
 STATISTIC AL ANALYSIS  
14.1 Statistical Design and Analyses  
All analyses will be pre -specified in a Statistical Analysis Plan to be finalized with FDA prior to database  
lock.  
  
A group sequential d esign will be employed with one interim analyses for safety and futility (n= 21) and a  
second interim analysis for safety  and futility (n=81).   At the request of FDA, the efficacy look was  
dropped prior to conducting the n=81 evaluation.  
  
All calculations  will be performed using SAS statistical software, version 9.3 or later, and StatXact,  
version 10 or later.  All efficacy and safety data will be displayed in tables and listings separately for each  
treatment group. Post -Text TLFs will be provided in col lated electronic MS Word .rtf files (i.e. table  
columns and rows appear in MS Word Table format).  
 
The statistical analyses of the study will be conducted in a GCP environment (ICH E6).   
 
There will be an independent statistical reporting group (ISRG) re sponsible for conducting all analyses;  
there will be separate unblinded biostatistician supporting the DSMB and a blinded biostatistician  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 22 
responsible for any protocol modifications.     
 
All patient data will be collected via the electronic medical record and in -house ICU telemetry systems.  
Dedicated research personnel will extract data to a de -identified study database for statistical analysis.  
14.2 Sample Size Calculation  
The sample size calculation of 1 98 subjects (2:1 allocation favoring the RLF -100 group) is required to 
detect a 2 2% absolute increase in the percent achieving respiratory failure resolution favoring the RLF -100 
group (assuming 50% success) and the SOC group (assuming 40% success) with 8 1% power and two -
sided overall 5% Type 1 error acc ounting for the group sequential design using the method in Schoenfel d.  
This degree of efficacy corresponds to a 0.5 2 hazard ratio.  
14.3 Study Populations  
The intent -to-treat (ITT) population will be based on all randomized patients receiving any study treatment.  
ITT will be analyzed as randomized.  
 
The safety population will be based on all randomized patients receiving any study treatment.  Safety will 
be analyzed as treated.  
 
The modified intent -to-treat (mITT) population will exclude untreated patients as well as ineligible 
patients; this will be the primary efficacy population.   The primary analysis set will not condition on any 
post-randomization out comes.  
 
In the event that >5% of the mITT population experience a major protocol deviation that impacts the 
primary efficacy endpoint, such cases will be excluded and a Per Protocol (PP) population will be 
constructed and the primary efficacy endpoint anal yses will be repeated for the PP population.  A BDRM 
will be held to review and to determine such major deviations  which would make it difficult to evaluate the 
study therapy , e.g. going on an  approved Critical COVID -19 therapy (none currently exist) or pr emature 
withdrawal from study.  The BDRM will be conducted at study completion to determine final mITT and PP 
population membership.  
14.4 Statistical Methods  
The primary analyses will be based on the modified intent -to-treat (mITT) population.   
All analyses wil l be conducted according to the treatment policy strategy to handle intercurrent events.   In 
the event of any dropouts, the BDRM will discuss how to best count these patients in the primary analysis 
and then in a sensitivity analysis.   
Evaluation of the p rimary efficacy endpoint (cu mulative distribution through Day 28) will be analyzed by a 
pre-defined proportional hazard model to include age (<65, >65 years), baseline NIAID score (2, >2), RDR 
(<150 mmHg, >150 mmHg), previous anti -viral therapy for COVID -19 (none, any), and study treatment as 
covariates  (primary) ; the proportional hazard model will be used to estimate unbiased treatment effects 
while controlling for these four baseline covariates. To count in the accruing numerator, the event must be 
confir med by the site to last for at least 7 days  with Day 28 survival .  SAS PROC PHREG will be used for 
these analyses.  See Section s 13.3-4 for rules to count respiratory failure resolution and the handling of 
intercurrent events  and dropouts .   
 
The key secondary efficacy endpoint will be the  percent achieving a NIAID Score 6-8 by Day 28/exit 
(primary) and by Day 60 (secondary) and will be analyzed by comparing success percents.  Patients who 
die or withdraw will not be counted as achieving success ( event).  The primary analysis will be a logistic 
regression model contain ing the same covariates as the primary efficacy endpoint.   The percents achieving 
success by Day 28/exit will also be compared using a two -sided Fisher Exact test.  
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 23 
The survival curve will be displayed using Kaplan -Meier lifetables to account for censoring in the 
estimation of the Day 28 and Day 60 survival outcomes; Greenwood’s formula will be used to estimate 
Day 28 outcomes with two -sided 95% confidence intervals c onstructed to compare  the treatment group 
differences.  The  same proportional hazard model as for the primary efficacy endpoint will be used to 
analyze survival; in addition, an unstratified log rank test will be performed.  
 
The other time to (favorable) event outcomes will also be assessed using cumulative distributions through 
Day 28 with an additional evaluation at Day 28; these outcomes include the time to ICU discharge, time on 
invasive mechanical ventilation, time on non -invasive ventilation, time to  discharge alive, and time to 
resolution of organ failure.  These endpoints will be analyzed and displayed the same way as the time to 
respiratory failure resolution  with the exception of just through Day 28 .  Two-sided 95% confidence 
intervals will be dis played for the Day 28 success rate differences in the same manner as for the key 
secondary efficacy endpoint.  Any deaths  or placement on ECMO on or before Day 28,  irrespective of a n 
earlier favorable event , or withdrawals without the favorable event  ever occurring will be counted as 
failures at Day 28; only documented favorable events will be counted as success in the distribution 
construction  and the denominator will include all mITT patient per treatment group . The Day 28 failure 
imputation  allows the cumulative distribution to align with the calculation of mean days saved ; thus, 
patients withdrawing earlier than Day 28 or not reaching a favorable event by Day 28 will be counted as 
failures a t Day 28 in the construction of the time to event lifetables; this is consistent with how favorable 
events were  handled  for remdesivir.  See Section s 13.3-4 for the handling of intercurrent events  and 
dropouts .    
 
The mean NIAID score will further be displayed over time.  The area under the curve will al so be 
calculated and compared using an unpaired t -test.  Patients dying prior to Day 28  (then Day 60) will be 
carried through Day 28  (then Day 60) as being dead  (NIAID=1) .   
 
The NIAID score will further be assessed for the change from baseline to Day 28/e xit and then to Day 
60/exit .  A mixed model repeated measures (MMRM) containing the same covariates as the primary 
efficacy endpoint will be performed to explore the impact of modeling serial data; an unstructured 
covariance symmetry will be assumed; in th e event that the unstructured covariance structure does not 
converge, then an autoregressive (1) structure will be tried, and if that does not work, then a Toeplitz 
structure will be tried.   
 
Other continuous variables, e.g., blood pressure, respiratory  rate, tidal volume, organ function 
measurements will be summarized by mean ± standard deviation, median, and range. Categorical variables, 
e.g., lung injury score, chest X -ray findings, will be summarized by frequency and corresponding % 
incidence.  
14.5 Interim Analys is, Futility/Safety  
Two pre -planned interim analyses will be conducted (n=21 initially, then an additional n=81).  There will 
be 81% power and two -sided 5% overall Type I error to assess the primary endpoint with a total of 198 
patients.  The DSMB recommended that the sample size be increased to detect a smaller clinically 
meaningful difference for the primary efficacy endpoint (reduc ed from 25% to 22%).  
The first interim analysis will be reviewed by the independent DSMB based on unblinded, unmasked data 
upon completion of 7 -day data collection in the first 21 patients. DSMB meeting minutes will be recorded 
and provided to FDA.  An un masked/unblinded analysis will be performed for the independent DSMB in 
order to assess safety and efficacy. Safety determinations will entail a review of AEs and SAEs by the 
independent Data Safety and Monitoring Board in consultation with FDA.  Based on this evaluation, the 
Sponsor will decide whether to permit adding additional study sites.  
If the decision is made to continue the study, the next interim analysis will be performed once the next 81 
patients complete the Day 28 evaluation for a safety  and f utility determination.  As per FDA, the study will 
continue enrollment to 1 98 patients.   
The details of the futility analysis follow.  The futility analysis was conducted when 81 of the original 144 
planned patients completed the study.  If the conditiona l power, under the alternative hypothesis is less 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 24 
than 10%, then the study will stop for futility.  𝐶𝑃=Φ(𝜇√1−𝑡+𝑧1−𝑝√𝑡
1−𝑡−𝑧0.975
√1−𝑡), where 𝑡=81/144 
and p is the current corresponding one -sided p -value.  The one -sided p -value to stop if the interim  analysis 
occurs at exactly 81 patients will be 0.5949.  This stop is non -binding and the D SMB will have the ability 
to continue if they see a positive signal in a secondary endpoint.  This futility assessment will not spend 
any Type 1 error which will rem ain at 0.05.  
The final sample size of 1 98 subjects (2:1 allocation favoring the RLF -100 group) is required to detect a 
22% absolute increase in the percent with respiratory failure resolution by Day 28 for the RLF -100 group 
(assuming 62% success) and the SOC group (assuming 40% success) with 8 1% power and two -sided 
overall 5% Type 1 error accounting for the group sequential design using the Schoenfeld method.  
The DSMB will advise regarding the favorable benefit/risk associated with e arly efficacy with safe ty.   
 HYPOTHESIS TESTS  
15.1 Treatment Comparisons  
Hierarchical testing will be used to preserve the Type 1 error associated with multiple endpoints (per FDA 
guidance)  in pursuit of additional labeling claims beyond the primary efficacy endpoint .  Hierarchical testing 
will not apply to the interim analyses; it will only apply to the final analysis. The testing order follows with 
two-sided p=0. 05 required to continue tes ting for additional label claims : 
Primary Outcome Measure:   
 
1) Cumulative distribution of the time to respiratory failure resolution with concurrent survival through 
Day 28 (primary) using all mITT patients.  
 
Key Secondary Measure:  
 
2) NIAID Ordinal Scale for Clinical Improvement reaches NIAID Score 6 -8 by Day 28 /exit (primary) ; 
percent achieving a NIAID Score 6 -8 will be evaluated  using all mITT patients ; Day 60/exit 
(confirmatory ) 
 
Secondary Outcome Measures (through Day 28  except for survival through both Day 28 and Day 60 ) 
3) Time to ICU discharge using all mITT patients  
4) Time on invasive mechanical vent ilation  using all mITT patients  initially on invasive mechanical 
ventilation   
5) Time on non -invasive ventilation using all mITT patients initially on non -invasive ventilation  
6) Time to hospital discharge using all mITT patients  
7) Overall survival using all mITT patients  
8) NIAID area under the curve using all mITT patients  
9) Multi -system organ  failure using all mITT patients.  
15.2 Prim ary Hypothesis  
The null hypothesis (H 0) is that there is no difference in the c umulative distribution (CD) for the time to 
respiratory f ailure resolution by Day 28 with Day 28 survival as primary  while the alternative hypothesis 
(Ha) is that there is a RLF -100 advantage in the CD:  
H0: CD RLF-100<CD PLA 
Ha: CD RLF-100>CD PLA 
15.3 Primary  Efficacy  Endpoint: Time to Respiratory Failure Resolution  
The primary o utcome measurement is the cumulative distribution  which shows  when resolution occurs for 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 25 
each treatment group.  Resolution must last for at least 7 days and start by Day 28; patients must be alive 
on Day 28.  In accordance with the treatment policy strategy, d eaths  and going on ECMO during the first 
28 days are coun ted as failures ; they are counted in the Day 28 denominator to permit the area under the 
curve to correspond to event -days saved .  The mITT patients per treatment group are the respective 
denominator s.   The data will be analyzed using a pre -defined proportional hazards model (primary) and 
unstratified log rank test (secondary); the hazard ratio and two -sided 95% confidence interval will be the 
critical statistic s; in addition, a two -sided 95% confiden ce interval will be computed for the Day 28 
outcome .  A 20% absolute improvement in the Day 28 success rate is deemed to be clinically meaningful.  
A 40% success rate is expected for Placebo + Maximal SOC while a > 50% success rate is expected for 
RLF-100 +  Maximal SOC.  
Sensitivity analyses are also planned ; see Section 13.4.  The BDRM will consider the most likely outcome 
on a patient -by-patient basis.  However, a tipping point analysis using the proportional hazard model will 
be performed where all RLF100 -1 patients dropping out will initially be considered as failures while all 
placebo patients will initially be considered to be successes.  The two -dimensional tipping point analysis 
will shift the balance over the spectrum of all independently being succes ses and all being failures.   
The mITT population will be used for the analysis.  
15.4 Key Secondary Efficacy Endpoint: Exit NIAID Score Reaches 6 -8  
The key secondary outcome measurement is the change in NIAID Score from pre -treatment baseline 
through Day 28 /exit (then Day 60/exit). Deaths are carried forward using NIAID Score=1 while, for 
withdrawals, the last value before Day 28 (60) is used for the Day 28 (60)/exit outcome.  The denominator 
is fixed per treatment group.  The data will be analyzed using a p re-defined logistic regression model 
(primary) and Fisher Exact test (secondary); the proportion achieving NIAID Score 6 -8 by Day 28/exit 
(primary) and by Day 60/exit (confirmatory) will be presented as the key summary measure to be 
estimated from the life table.    A 20% absolute improvement in the Day 28 (and Day 60) percent  is deemed 
to be clinically meaningful.  A 40% success rate is expected for Placebo + Maximal SOC while a > 60% 
success rate is expected for RLF -100 + Maximal SOC.   
 
The same two -dimensio nal tipping point analysis will be conducted as for the primary efficacy analysis 
except using a logistic regression model.  
 
In addition, a MMRM model using the same covariates will be run for the change from pre -treatment 
baseline to Day 28/exit using the  same baseline covariates for the primary efficacy endpoint.  The mean 
change from pre -treatment baseline to Day 28/exit will be the endpoint of interest.  The analyses will be 
repeated at Day 60/exit (confirmatory).   The MMRM model will use an unstructure d covariance symmetry 
will be assumed ; in the event that the unstructured covariance structure does not converge, then an 
autoregressive (1) structure will be tried, and if that does not work, then a Toeplitz structure will be tried.  
The mean change from pre-treatment baseline to Day 28/exit (primary) and Day 60/exit (confirmatory) 
will also be of interest.   
 
The mITT population will be used for these analyses.  
15.5 Secondary Efficacy Endpoint s: Time to Favorable Events 
These secondary efficacy endpoints will be analyzed in the same manner as the  primary efficacy endpoint.  
For each such endpoint, the outcome measurement is the cumulative distribution which is a figure that 
shows when  the favorable event  occurs for each treatment group.  Any deaths or placement on ECMO on or 
before Day 28, irrespective of an earlier favorable event, or withdrawals without the favorable event ever 
occurring will be counted as failures at Day 28; only documented favorable e vents will be counted as 
success in the distribution construction and the denominator will include all mITT patient per treatment 
group. The Day 28 failure imputation  permit s the area under the curve to correspond to event -days.  The 
denominator is fixed p er mITT treatment group.  To  count in the accruing numerator, the event must be 
confirmed by the site to last for at least 7 days .  The data will be analyzed using the same pre-defined 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 26 
proportional hazards model (primary) and an unstratified log rank test (secondary); the hazard ratio will be 
the critical statistic.   
 
The mITT population will be used for the analysis.  
15.6 Secondary Efficacy Endpoint:  Survival  
Kaplan -Meier lifetables for surviva l will be constructed through Day 28 (primary) and t hrough Day 60 
(confirmatory). Survival is defined as not having died as ascertained from the medical record.  If death 
occurs post discharge and prior to Day 28  (or Day 60) , study personnel will attempt to  obtain a death 
certificate but may not succeed in the current emergency.  A lif etable will be generated; a proportional 
hazard model will be run to include the four previously stated endpoint covariates (primary) and an 
unstratified log rank test (seconda ry) will also be run; the hazard ratio will be the critical statistic.  All 
deaths from any cause are included in the survival analysis  as events ; the 28-day and 60-day all -cause 
mortality percents will be estimated from the respective Kaplan -Meier lifetab les. The Day 28 and Day 60 
estimates from the lifetables will be compared using two -sided 95% confidence intervals.   
 
The mITT population will be used for the analysis.   
15.7 Secondary Efficacy Endpoint: NIAID 8 -point Scale Area Under the Curve  
The NIAID 8 -point scale will be used to construct the area under the curve.  Deaths will be counted as 
NIAID Score =1 while the NIAID Score will be scaled by multiplying the AUC times 27/D where D is the 
number of days on study minus 1.  The AUC will be co mputed for each patient to perform the AUC 
comparison using an unpaired t -test for the mean difference (and average difference per day).   
 
The mITT population will be used for the analysis.  
15.8 Secondary Efficacy Endpoint: Multi -system Organ Failure   
The days  free of multi -system organ failure will be computed; organs include sepsis, blood, brain, heart, 
liver,  and kidneys.  Any such indication constitutes organ failure. The days free of multi -system organ 
failure will be assessed using the Schoenfeld method. The mean difference is the critical statistic.  
 
The mITT  population will be used for the analysis.    
15.9 Other  Efficacy Endpoint: Blood PaO2/FiO2 Ratio (while on MV)  
Blood PaO2/FiO2 ratio will be analyzed in the same manner as the NIAID Score MMRM  model excep t 
that data collection stops when invasive mechanical ventilation ends.  In addition, the percent improving by 
at least 100 points will be presented as a descriptive statistic.  
 
The mITT population will be used for the analysis.    
15.10  Exploratory  Efficacy Endpoint: Oxygenation Index   
The Oxygenation Index is considered an exploratory variable because it is inconsistently measured across 
sites.  Ideally, it is measured at every 24 hours and 28 days post intubation with additional endpoint 
determina tions through cessation of mechanical ventilation.  Time to normalization (last SaO2 value 
>95%) will be evaluated; this endpoint will also be analyzed in the same manner as the primary efficacy 
endpoint for the time to the successful event  with the requir ement to not relapse within 7 days .   
 
The mITT population will be used for the analysis.  
15.11  Other Exploratory Efficacy Endpoint: Improvement in Chest x -ray 
The RALES score will be ascertained by a blinded radiologist panel. The percent with improvement in 
chest x -ray over time will be independently determined by the panel.  Percent improving will be compared 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 27 
using a two -sided Fisher Exact test while the RALES  score distribution over time will be displayed 
descriptively.  
 
The population with available data will be used for the analysis.  
15.12  Laboratory Endpoint s: VIP and Inflammatory Markers  
The secondary laboratory outcome measure s are VIP, TNFα , IL6, and other in flammatory markers  as 
measured in the central laboratory .  Mean VIP per day will be compared using a paired t -test within 
treatment group and using an unpaired t -test between treatment groups per day.  The inflammatory markers 
will be evaluated for t ime to normalization (to be determined per endpoint prior to data base lock); th ese 
endpoint s will be analyzed in the same manner as VIP when treated as a continuous measure.  
The mITT population will be used for the analysis.  VIP and inflammatory markers are not required 
beyond the 165 patients enrolled mark.  
15.13  Overall Sa fety Endpoints  
Standard safety analyses are planned.   Adverse events will be coded in MedDRA.  The incidence, severity, 
relationship, and worst degree will be assessed with attention paid to AEs occurring during the first three 
days when infusion is to be administered.  The incidence of SAEs and deaths/withdrawals due to treatment 
will also be assessed.   The following additional adverse events are of special interest:  
• Diarrhea that leads to treatment discontinuation  
• Renal failure  
• Bleeding events  
• Liver toxi city 
• Hypotension/shock.  
All safety results will be presented separately for each treatment group. Safety endpoints will include 
adverse events, vital signs (VS), and relevant clinical chemistries and hematology parameters. Safety and 
tolerability will be assessed using two -sided Fisher Exact tests to compare RLF -100 vs. Placebo.  For each 
treatment group as well as for the difference, t wo-sided 95% confidence intervals will be computed for 
each system organ class and for any preferred terms with >10% incidence for either study tre atment.  
Mean changes from randomization baseline will be displayed for each serum chemistry and hematology 
parameter as well as the shift; unpaired t -tests will be used to compare RLF -100 vs. Placebo at designated 
study times. In addition, paired t -tests will be performed for the change from randomization baseline within 
each study treatment group.  
The safety population will be used for these analyses.  
 SOURCE DATA & DOCUMENTS  
16.1 Sources of Research Materials  
The following source data and documents will be co llected. All blood samples, except those taken for 
cytokine and arachidonate metabolite level monitoring, which would be part of this investigation, would be 
obtained in the normal course of clinical care of these patients as described above.  
16.2 Case Report Form  
The Case Report Form (CRF) is an integral part of the study and subsequent reports.  The CRF must be 
used to capture all study data recorded in the patient’s medical record.  The CRF must be kept current to 
reflect patient status during  the stu dy.  Only a patient screening and randomization number will be used to 
identify the patient.   
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 28 
16.3 Patient Identification  
Patient n ame, medical record number, age, gender, height, weight, ethnic background, residence address 
with zip code  will be collected.  
16.4 General Clinical Data  
Primary diagnosis, coexisting diagnoses / conditions, hospital length of stay  and outcome  will be collected.  
16.5 Lung Injury / ARDS Data  
PaO2/FiO2 ratio; PEEP/CPAP; peak, mean & plateau pressures; compliance (dyna mic and quasi -static); 
tidal volume; respiratory rate; minute ventilation, lung injury score, chest X -ray findings  will be collected.  
16.6 Laboratory Data  
Arterial blood pH, PC O2, PO2; electroly tes (Na, K, Cl, HC O3); renal function (BUN, serum creatinine); 
glucose, albumin & total plasma proteins; liver function tests; blood cell count; coagulation profile; lactic 
acid and D-Dimer  will be collected.   
16.7  Vital Signs, Respiratory and Hemodyna mic Data  
Blood pressure (systolic, diastolic, mean), heart rate, respiratory rate, cardiac output/cardiac index, 
pulmonary artery (PA) wedge pressure, systolic, diastolic & mean pressures (if PA catheter is in place), 
right atrial/central venous pressure, systemic  and pulmonary vascular resistance, systemic  02 delivery, daily 
urine output, daily fluid intake  will be collected.  
16.8 Medical Therapy Data  
The therapeutic milieu for RLF100 -001 – ICU-type settings during the COVID -19 pandemic – requires a 
thoughtful and prac tical approach to the capture of concomitant medications in clinical studies.  
Specifically, the capture of relevant concomitant medications is required under three circumstances:  
1. As part of a relevant medical history entry, where relevant medical histo ry is defined as relating 
to an inclusion or exclusion criteria;  
2. As part of an AE entry, for agents administered in response to the AE; and  
3. Agents of interest, namely Biotin, IL6, antiviral therapies, steroids, nitric oxide, epoprostenol 
(Flolan), p ressors (e.g., norepinephrine, epinephrine, Vasopressin), paralytics, anticoagulants, 
convalescent plasma, and tocilizumab (Actemra)  and other immunomodulators .   
Please note there is a unique dedicated CRF page for capturing concomitant use of convalescent plasma – 
no need for a duplicate entry on a concomitant medication form.  
Furthermore, sites will be asked to report unusual circumstances in their ICU that require medical therapy 
that can negatively affect the prognosis of a patient, e.g. eme rgence of treatment resistant bacteria leading 
to high mortality.  
16.9 Pharmacokinetic Sampling  
The pharmacokinetics of intravenous Aviptadil are well understood and do not require revalidation in this 
study.  
16.10  Blood Sampling  
Blood samples are obtained for bioche mical, electrolyte, and hematologic profiles per ICU protocol . Blood 
samples for cytokine (TNF -alpha, IL -6,  which  correlate  with the inflammatory  response are obtained 
before  infusion,  during infusion,  and at 12  hours , and then daily on day 5, da y 7 and day 28 or day of 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 29 
discharge . Leukotrine E4 (urine) and Plasma VIP levels are checked at the same intervals to ensure the 
delivery of the peptide into the circulation. Plasma is separated within 30 min, frozen and stored at -70 C 
until the assays are performed, by specific radio -immunoassays or ELISA . Additionally,  D-Dimer may be 
added when available .  The procedures for blood samples for cytokines, leukotrine E4 urine and VIP 
plasma are not required after enrollment  of the 165th evaluable p atient . 
 
 
  STUDY MONITORING  
17.1 Study Monitoring  
The study site s have been evaluated by the sponsor in conjunction with the CRO to determine suitability 
for the proposed study. Information reviewed included , but was not be limited to, facility details and site 
capabilities, past performance in similar studies, investigator, and s taff experience, ongoing studies at the 
site, projected enrollment in this study, and FDA or other agency audit findings. Prior to subject 
enrollment, a virtual study initiation visit will be completed by video conference  to ensure the following: 
IRB appro val has been obtained and documented prior to subject screening, the investigators and study 
personnel are appropriately trained and clearly understand the study, the investigators and study personnel 
accept the obligations incurred in undertaking this cli nical investigation.  
Periodic  remote  monitoring visits will be made in accordance with the approved monitoring plan at all 
active study sites throughout the clinical study to assure that the investigator obligations are fulfilled, and 
all applicable regula tions and guidelines are being followed. These visits will assure that the facilities are 
still compliant with study requirements , the protocol and investigational plan are being followed, the IRB 
has been notified of approved protocol changes as required,  complete records are being maintained, 
appropriate and timely reports have been made to the sponsor and the IRB, and the site Investigator is 
executing all agreed activities.   Given the public health crisis, these visits will be done  via virtual means 
and specific monitoring arrangements with each site.  
17.2  Data Safety and Monitoring  
All results from this study will be reviewed by a Data Safety and Monitoring Committee , chaired by Prof. 
Alfred Sommer, MD, MHS, Dean Emeritus of the Bloomberg School of Public H ealth . Membership of this 
committee will include: a clinician specialist in Critical Care Medicine, a biostatistician, and a lay patient 

           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 30 
advocate. The committee will critique the progress of the trial, carefully examine any incidents of adverse 
reactions, and may suggest appropriate revisions in the protocol. DSMB functions include, among others, 
ongoing assessment of unblinded data to determine whether any of the treatment arms show increased risk 
for AEs.  
17.3 Medical Monitor  
The Medical Monitor will review a nd approve the eligibility of all screened subjects, review all AEs, 
assess the benefits and risks of protocols on an ongoing basis, and work in collaboration with the IRB and 
DMC to identify safety signals and trends. In addition, the Medical Monitor will  be available for site 
questions regarding inclusion/exclusion criteria, protocol conduct, and safety. Trained and qualified 
physicians will be available to provide coverage during times when the medical monitor is unavailable. 
Sites will be provided with the Medical Monitor’s cell phone number for emergency situations. Otherwise, 
sites are instructed to contact the Medical Monitor through email. All critical conversations with sites will 
be documented by the Medical Monitor and reviewed periodically by the sponsor. Each month the Medical 
Monitor will receive a listing of protocol violations for review and identification of possible trends.  
17.4 Audits and Inspecti ons 
Contracts  with study sites will specify that sponsor or its representatives will have direct access to source 
data and documents for study monitoring , which may be done through virtual/electronic means . 
Additionally, the IRB and FDA may review source d ata following appropriate guidelines for this process.  
17.5  Institutional Review Board  
The study protocol and any amendments will be reviewed by the Advarra  Institutional Review Board 
(IRB). The IRB will review the informed consent form, their updates (if any) , and any written materials 
given to the pa rticipants. IRB approval will be obtained and documented prior to subject enrollment and 
screening. Before study initiation, the investigator must have written and dated approval from the IRB for 
the protocol, con sent form, subject recruitment materials/process (e.g., advertisements), and any other 
written information to be provided to subjects. The investigators will provide the IRB with reports, 
updates, and other information (e.g., Safety Updates, Amendments, an d Administrative Letters) according 
to regulatory requirements and Institution procedures. A detailed list of required regulatory documents, to 
be submitted to the sponsor, will be sent upon final approval of the protocol.  
 ETHICAL CONSIDERATIONS  
18.1 Ethical Co nsiderations  
Anticipated benefits to participants and others:  There are at present no satisfactory specific treatments for 
ARDS, or multiple organ dysfunction. Based on a large body of experimental work, there is reason to 
expect that RLF -100 ( aviptadil) m ay prove effective in increasing survival rates in COVID -19 patients 
with ARDS, as well as increasing blood 0 2, reducing organ failure and reducing cytokine cascades.  
Anticipated risks to participants and others:  The only anticipated risks are due to the side -effects noted 
above of hypotension, tachycardia  and watery diarrhea. Aviptadil has been evaluated in 4 species 
toxicology studies and the LD50 is more than 50x the exposure contemplated in this trial.  
18.2 Ethical  Conduct of the Study  
This study will be conducted in accordance with the ethical principles that have their origins in the 
Declaration of Helsinki, in compliance with the approved protocol, GCP, and applicable regulatory 
requirements.  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 31 
18.3  Informed Consent  
Direct patient consent is always preferred if possible, but p atients are  sometimes unable to give consent in 
this setting.  Under these circumstances, t he patient’s legally authorized representative (LAR)  must be 
capable of understanding the nature of this s tudy and its potential risks, discomforts, and benefits. Study 
physicians or their delegate will obtain consent after they have fully explained the study purpose and 
procedures , and the LAR  has demonstrated an understanding of the protocol, willingness to participate, and 
competency to consent.  The investigator or their delegate must ensure that subjects are clearly and fully 
informed about the purpose, potential risks, and other critical issues regarding clinical trials in which they 
volunteer to particip ate. Preparation of the site -specific consent form is the responsibility of the site 
Principal investigator and must include all elements required by CFR 21 Part 50.25 and the IRB.  
 DATA HANDLING & RECORD KEEPING  
19.1 Data Capture  
An investigator is required to prepare and maintain adequate and accurate case histories designed to record 
all observations and other data pertinent to the investigation on everyone  treated with the investigational 
product or entered as a control in the i nvestigation.  
19.2 Data Collection  
No manual data collection is anticipated in the ICU. Data will be extracted from the EMR  and other 
sources  by hospital clinical research staff in a HIPAA -compliant, de -identified manner and transferred to 
the study database . 
19.3 Retention of Records  
The investigator must retain investigational product disposition records, case report forms, and source 
documents for the maximum period required by applicable regulations and guidelines, or in accordance 
with institution pro cedures, and at least for 10 years.  This is study practice in the study sites.  
19.4 Use of Information and Publication Policy  
All publications will be reviewed by the sponsor for accuracy before submission to peer -reviewed journals 
or scientific meetings. Abstr acts will be submitted for review at least 10 days before submission, and 
publications should be submitted for review at least 30 days before submission. The study will be posted to 
Clinicaltrials.gov, and results will be reported in accordance with Clinic altrials.gov guidelines.  
  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 32 
 REFERENCES  
Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman  GA, Matthay  MA, 
Ware  LB. Fas and fas ligand  are up-regulated  in pulmonary  edema fluid and lung tissue of 
patients with acute lung injury and the acut e respiratory distress syndrome. Am J Pathol.  
2002;161:1783 -1796.  
Alessandrini F, Thakkar M, Foda HD, Said SI, Lodi R, Pakbaz H, Schraufnagel  DE. Vasoactive 
intestinal peptide enhances lung preservation. Transplantation. 1993;56:964 -973. 
Antonsen K, Wetterslev J, Bonde J. Incidence, severity and mortality of acute respiratory failure in 
Denmark Ugeskr Laeger. 2000;162:2876 -2881.  
Arroliga AC, Gh amra ZW, Perez Trepichio A, Perez Trepichio P, Komara JJ Jr, Smith  A, 
Wiedemann  HP. Incidence  of ARDS  in an adult  population  of northeast Ohio. Chest.  
2002;121:1972 -1976.  
Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini  JJ, Matthay  
MA, Pinsky  MR, Spragg  R, Suter  PM. The American -European Consensus  Conference  on ARDS,  
part 2: Ventilatory,  pharmacologic,  supportive therapy, study design strategies, and issues 
related to recovery and remodeling. Acute  respiratory  distress  syndrome.  Am J Respir  Crit Care  
Med.  1998;157:1332 - 1347.  
Berisha H, Foda H, Sakakibara H, Trotz M, Pakbaz H, Said SI. Vasoactive intestinal peptide 
prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol. 1990;259:L151 -L155.  
Bersten  AD, Edibam  C, Hunt  T, Moran  J; Australian  and New  Zealand  Intensive Care Society 
Clinical Trials Group. Incidence and mortality of acute lung injury and  the acute  respiratory  
distress  syndrome  in three  Australian  States.  Am J Respir Crit Care Med.  2002;165:443 -448. 
Cui L, Hung HM, Wang SJ ; Modification of sample size in group sequential clinical trials.  
Biometrics. 1999;55(3):853 -857. 
Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, Gomariz RP. Vasoactive intestinal 
peptide (VIP) and pitu itary adenylate cyclase -activation polypeptide (PACAP) protect SOC e 
from lethal endotoxemia through the inhibition of TNF -alpha and IL -6. J Immunol. 
1999;162:1200 -1205.  
Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory fail ure? Eur 
Respir J. 1997;10:1297 -1300.  
FDA Guidance for Industry. COVID -19: Developing drugs and biological products for treatment or 
prevention .  Center for Drug Evaluation and Research, May 2020  
Foda HD, Iwanaga T, Liu L -W, Said SI. Vasoactive intestinal peptide protects against  HCl-induced  
pulmonary  edema  in rats. Ann NY Acad  Sci 1988;527:  633- 636. 
Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, Garcia - Gomez  M, Leceta  J, 
Juarranz  Y. Time -course  expression  of Toll-like receptors  2 and  4 in inflammatory  bowel  disease  
and homeostatic  effect  of VIP. J Leukoc  Biol. 2005;78:491 -502. 
Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, Le Y, Wang JM, Oppenheim JJ, Lloyd 
AR. Cutting edge: vasoactive intestinal peptide acts as a pot ent suppressor of inflammation in 
vivo by trans -deactivating chemokine receptors. J Immunol. 2003;171:4990 -4994.  
Hashimoto S, Kobayashi A, Kooguchi K, Kitamura Y, Onodera H, Nakajima H. Upregulation  of 
two death  pathways  of perforin/granzyme  and FasL/Fas  in septic acute respiratory distress 
syndrome. Am J Respir Crit Care Med. 2000;161:237 - 243. 
Hudson  LD, Steinberg  KP. Epidemiology  of acute  lung injury  and ARDS.  Chest. 1999;116:74S -82S. 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 33 
Hughes M, MacKirdy FN, Ross J, Norrie J, Grant IS; Scottish Intensive Care Society.  Acute  
respiratory  distress  syndrome:  an audit  of incidence  and outcome  in Scottish  intensive  care units.  
Anaesthesia.  2003  Sep;58(9):838 -45. 
Lewandowski K, Metz J, Deutschmann C, Preiss H, Kuhlen  R, Artigas A, Falke KJ. Incidence, 
severity, and mortality of acute respiratory failure in Berlin, Germany. Am J Respir Crit Care 
Med. 1995 Apr;151(4):1121 -5. 
Li L, Luo ZQ, Zhou FW, Feng DD, Guang CX, Zhang CQ, Sun XH. Effect of vasoactive intestinal 
peptide on pulmonary surfactants phospholipid synthesis  in lung explants. Acta Pharmacol Sin.  
2004;25:1652 -1658.  
Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, Bonde J. Incidence 
and mortality after acute respiratory failure and acute  respiratory  distress  syndrome  in Sweden,  
Denmark,  and Iceland.  The ARF  Study Group. Am J Respir Crit Care Med.  1999;159:1849 -
1861.  
Mason R. Pathogenesis of COVID -19 from a cell biologic perspective. Eur Respir J. April 9 Epub 
ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/  
Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, 
Gimbrone MA Jr, Hoffman E, Hubmayr RD, Leppert M, Matalon S , Munford  R, Parsons  P, 
Slutsky  AS, Tracey  KJ, Ward  P, Gail DB, Harabin  AL. Future research directions in acute lung 
injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir 
Crit Care Med. 2003;167:1027 -1035.  
Matute -Bello  G, Liles  WC, Steinberg  KP, Kiener  PA, Mongovin  S, Chi EY, Jonas M,  Martin  TR. 
Soluble  Fas ligand  induces  epithelial  cell apoptosis  in humans  with acute  lung injury  (ARDS).  J 
Immunol.  1999;163:2217 -2225.  
Matute -Bello G, Martin TR. Science review: apoptosis in acute lung injury. Crit Care. 2003;7:355 -
358. 
Misra  BR, Misra  HP. Vasoactive  intestinal  peptide,  a singlet  oxygen  quencher.  J Biol Chem.  
1990;265:15371 -15374.  
Mulligan  MS, Polley  MJ, Bayer  RJ, Nunn  MF, Paulson  JC, Ward  PA. Neutrophil - dependent  acute  
lung injury.  Requirement  for P-selectin  (GMP -140).  J Clin Invest. 1992;90:1600 -1607.  
Nagahiro I, Yano M, Boasquevisque CH, Fujino  S, Cooper JD, Patterson GA. Vasoactive intestinal 
peptide ameliorates reperfusion injury in rat lung transplantation. J Heart Lung Transplant. 
1998;17:617 -621. 
Nolan  S, Burgess  K, Hopper  L, Braude  S. Acute  respiratory  distress  syndrome  in a community  
hosp ital ICU.  Intensive  Care  Med.  1997;23:530 -538. 
Pakbaz H, Liu L -W, Foda HD, Berisha H, Sais SI. Vasoactive intestinal peptide (VIP) as a 
modulator of PAF -induced lung injury. Clin Res 1988;36: 626A.  
Pakbaz H, Higuchi J, Foda HD, Said SI. Phospholipase C – induced acute lung injury and its 
attenuation by vasoactive intestinal peptide (VIP). Am Rev Respir Dis 1991; 43:A577.  
Pakbaz  H, Foda  HD, Berisha  HI, Trotz  M, Said SI. Paraquat -induced  lung injury: prevention  by 
vasoactive  intestinal  peptide  and related  peptide  helodermin.  Am J Physiol.  1993;265:L369 -
L373.  
Pakbaz  H, Berisha  H, Sharaf  H, Foda  HD, Said SI. VIP enhances,  and nitric  oxide synthase inhibitor 
reduces, survival of rat lungs perfused ex vivo. Ann NY  Acad Sci  1994;723:426 -428. 
Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a 
neuropeptide? FASEB J. 2004;18:1325 -1334.  
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 34 
Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. 
Incidence and outcomes of ac ute lung injury. N Engl J Med.  2005;353:1685 -1693.  
Said SI, Berisha  HI, Pakbaz  H. Excitotoxicity  in the lung:  N-methyl -D-aspartate - induced, nitric 
oxide -dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by 
inhibitors of poly(AD P-ribose) polymerase. Proc Natl Acad Sci U S A.  1996;93:4688 -4692.  
Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: modulation by 
vasoactive intestinal peptide. Regul Pept. 2000;93:21 -29. 
Schoenfeld, DA. "A simple algorithm for designing group sequential clinical 
trials."  Biometrics  57.3 (2001): 972 -974. 
Schoenfeld, DA, Bernard GR. Statistical evaluation of ventilator -free days as an efficacy measure 
in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med: August 
2002;30: 1772 -1777.  
Sharma  V, Delgado  M, Ganea  D. Granzyme  B, a new player  in activation -induced cell  death,  is down -
regulated  by vasoactive  intestinal  peptide  in Th2 but not Th1 effectors. J Immunol.  
2006;176:97 -110. 
Sigvaldason K, Thornormar K, Bergmann JB, Reynisson K, Magnusdottir H, Stefansson TS, 
Jonsson S. The incidence and mortality of ARDS in Icelandic intensive care units 1988 -1997. 
Laeknabladid. 2006;92:201 -207. 
Takamatsu  J, Shima  K, Sakakibara  H, Trotz  M, Said SI. Anaphylaxis  in guinea  pig lungs: attenuation 
of physiologic and bioche SOC al consequences by vasoactive intestinal peptide. Am Rev 
Respir Dis  1991;143:A44.  
Thomsen  GE, Morris  AH. Incidence  of the adult  respiratory  distress  syndrome  in the  state of Utah.  
Am J Respir  Crit Care  Med.  1995;152:965 -971. 
Todd S, Valdés -Márquez E, West J. (2002). A practical comparison of blinded methods for sample 
size reviews in survival data clinical trials. Pharm Stat. 2012; 11(2):141 -8. 
Tuncel  N, Tore F, Sahinturk V, Ak D, Tuncel M. Vasoactive intestinal peptide inhibits 
degranulation and changes granular content of mast cells: a potential therapeutic strategy in 
controlling septic shock. Peptides. 2000;21:81 -89. 
Udobi  KF,  Childs  E,  Touijer   K.  Acute   respiratory   distress   syndrome. Am Fam Physician.  
2003;67:315 -322. 
Valta P, Uusaro A, Nunes S, Ruokonen E, Takala J. Acute respiratory distress syndrome:     
frequency,     clinical     course,     and     costs     of      care.     Crit Care Med.  1999;27:2367 -
2374.  
Villar  J, Slutsky  AS. The incidence  of the adult  respiratory  distress  syndrome.  Am Rev Respir Dis.  
1989;140:814 -816. 
Ware   LB,   Matthay   MA.    The    acute    respiratory    distress    syndrome. N Engl J Med.  
2000;342:1334 -1349.  
Warren MA, Zhao Z, Koyama T et  al (2018) Severity scoring of lung edema on the chest 
radiograph is associated with clinical outcomes in ARDS. Thorax. 
https://doi.org/10.1136/thoraxjnl2017 -211280  
Webster NR, Cohen AT, Nunn JF. Adult respiratory distr ess syndrome --how many cases in the 
UK? Anaesthesia. 1988;43:923 -926. 
 
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 35 
 APPENDIX A; SCHEDULE OF EVENTS  
 
  Schedule of Events: Appendix A  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 8 -
Day 27  Day 28  
 Day 60  
Procedures  Screening  1st 
Dosea During 
infusion  2nd 
Dosea During 
infusion  3rd 
Dosea During 
infusion  Follow -
Up Follow -
Up Follow -
Up Follow -
Up Follow -
Up Follow -Up 
D28 or 
day of 
discharge  Day 28 
Follow -
up 
Phone 
Call Day 60 
Follow -
up 
Phone 
Call 
Informed Consent Process  X               
Evaluation of Exclusion & 
Inclusion Criteria  X               
Medical 
History/Demographics  X               
Confirm Eligibility and 
Randomization   X              
Vital Signs (Pulse, 
Respirations)b X X Xb X Xb X Xb         
Blood Pressurec X X  X  X          
Weight  X X  X  X  X X X X  X   
CNS Assessment  X X  X  X  X X X X  X   
Urine Output and Fluid 
Intake   X  X  X  X X X X     
IV Administration of 
Study Drug   X X X X X X         
ICU Telemetry: ECG   X  X  X  X X       
PaO2/FiO2 Ratio  X X  X  X  X X X X  X   
CBC (Complete Blood 
Count with Differential & 
Platelets)  X X  X  X  X X X X  X   
CMP (Complete Metabolic 
Panel)  X X  X  X  X X X X  X   
ABG - Non-ventilated 
subjects (for PaO2/FiO2 
ratio): pH, pCO2, pO2, 
CO2, HCO3 per ICU 
protocol  X        X   X g    
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 36 
 
 
  Schedule of Events: Appendix A  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 8 -
Day 27  Day 28  
 Day 60  
Procedures  Screening  1st 
Dosea During 
infusion  2nd 
Dosea During 
infusion  3rd 
Dosea During 
infusion  Follow -
Up Follow -
Up Follow -
Up Follow -
Up Follow -
Up Follow -Up 
D28 or 
day of 
discharge  Day 28 
Follow -
up 
Phone 
Call Day 60 
Follow -
up 
Phone 
Call 
ABG - Ventilated subjects   
(for PaO2/FiO2 ratio):  
 pH, pCO2, pO2, CO2, 
HCO3 per ICU protocolh X X X X X X X X X X X X X   
Murray Score  X X  X  X  X X X X  X   
D-Dimer  X X  X  X  X X X X  X   
PT/INR/aPTT  X               
Lactic Acid  X X  X  X  X X X X  X   
Serum/Urine Pregnancy 
Test (Either Serum or 
Urine, not both)  X               
HIV (based on history, no 
HIV testing is required)  X               
Cytokines: Circulating 
IL6e, j  X Xe X Xe X Xe  X  X  X   
Cytokines: TNFae, j  X Xe X Xe X Xe  X  X  X   
Urine Leukotrienef, j  X  X  X   X  X  X   
Plasma: VIP (Vasoactive 
Intestinal Polypeptide)f,j  X  X  X   X  X  X   
Study Drug Pharmacy 
Dispensing   X  X  X          
Assess for Adverse 
Eventsd  X X d X X d X X d X X X X X X   
Assess Concomitant 
Medications  X X  X  X  X X X X X X   
NIAID Ordinal Scale for 
Clinical Improvement   X  X  X  X X X X X X X X 
Chest X -ray (sub -study 
sites only) i TBD =>                
           
NeuroRx, Inc. RLF100 -001 Protocol for Critical COVID -19  V 4.7 26 -December -2020 Page | 37 
Footnotes:  
a Each dose is administered over 12 hours at the same time each day. Date and time of start and end of infusion will be recorded.   
b Pulse and respirations will be continuously monitored but will be recorded prior to and at 2, 4, 6, 8, 10 and 12 -hour timepoints after each 
dose escalation . 
c Blood pressure will be recorded prior to infusion and at 2, 4, 6, 8 and 1 2-hour timepoints throughout the infusion.     
d Infusion reactions/adverse events check at 2 hours, and then continuously throughout the 12 -hour infusion period.     
e Collected pre -dose, 2 hours and  12 hours after the start of  each infusion over 3 days , then on Day 5, Day 7 and Day 28 / or day of discharge 
if sooner .    
f Plasma VIP and u rine leukotriene  E4 should be collected prior to initiating each dose escalation , on days 1, 2,3; then at day 5, day 7 and 
day 28 or day of discharge if sooner .    
g  Only on Day 10.     
h  Ventilated Patients only - ABGs as follows:  
Days 1, 2 and 3 - Pre-Dose and at 6 hours after infusion begins (± 1 hour).  
Day 4 through discharge - once daily.     
i Chest X -ray images to be captured via a sub -study at a subset of identified sites only , specifics ox X -ray timings and number TBD.     
j Procedures for blood samples for cytokines ; urine leukotriene ; and plasma VIP are not required after  165 evaluable patients have been 
enrolled.     
 